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Abstract 
The rise in the prevalence of overweight and obesity has reached record levels and has 
gained national attention with respect to public health initiatives.  The race to develop a 
pharmaceutical product that can help individuals lose weight has resulted in the release of 
several fatal products that have been withdrawn.  Meanwhile, the growth of direct to 
consumer advertising has grown dramatically greatly increasing the autonomy of 
patients.  This paper analyzed the extent to which firms’ respond to the market conditions 
and research regarding drug advertising.  A unique dataset of print advertisements 
collected from 26 popular magazines and 2 medical journals was analyzed to assess the 
textual and visual cues of weight-loss advertisements.  Analyses reveal a concentration of 
both prescription and over-the-counter advertisements in select magazines varying 
depending on the target audience.  The targeting of certain populations was further 
displayed through the systematic differences in the use of effectiveness and risk 
information.  This paper provides insight into the textual and visual cues used to increase 
demand and profits of the pharmaceutical firms marketing weight-loss products 
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1. Introduction 
The recent growth in the prevalence of overweight and obesity over the past 
twenty years (Ogden et al., 2006) has created a race to develop a drug (either over-the-
counter or prescription) that could safely and effectively help individuals lose weight.  
This race has led to a rise in the number of over-the-counter products that claim to have 
miraculous effects.  The over-the-counter market has been seen as possible supplement to 
help individuals lose weight, but reports of adverse event for products containing PPA 
and ephedra has introduced a stigma to these products. (Allison, Fontaine, Heshka, 
Mentore, & Heymsfield, 2001).  Similarly, the prescription market has faced two 
withdrawals (Pondimin and Redux) severely hurting its sales and revenue due to the fear 
of pulmonary hypertension and heart valve issues (Stafford & Radley, 2003).  While 
some of these drugs are considered dangerous and potentially fatal, consumers are still 
attracted to these products with the notion that the benefits are greater than the risks.  To 
more fully understand the current equilibrium of consumption of these weight-loss 
agents, this paper will analyze how firms respond to the current market conditions 
through a systematic analysis of the print advertisements for all weight-loss products.   
The pharmaceutical firms producing weight-loss products face economic 
constraints that restrict their behavior.  The two main constraints are: governmental 
regulations and consumer behavior.  Economic theory explains that firms want to 
maximize profits.  These firms will respond to these regulatory policies and market 
conditions to create advertisements that elicit the most response from consumers.  
Throughout this paper, the regulatory policies for print and mass media advertisements 
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will be used to assess how pharmaceutical companies use information about consumer 
behavior and decision making to develop the most effective advertisement.   
In order to assess the marketing strategies of the pharmaceutical firms, a unique 
dataset of over-the-counter and prescription weight-loss products from twenty-six 
popular magazines will be analyzed and content coded.  The analysis of how over-the-
counter advertisements affect consumer behavior is similar to that of regular 
advertisements.  These advertisements work to persuade individuals to purchase a 
product through convincing or changing the buyer’s opinion about the effectiveness of 
the given product.  Consequently, common techniques and methods include use of sexual 
appeal, product effectiveness, convenience, length of time to seeing result, and emotional 
happiness.  These appeals and claims can be extremely effective within the weight-loss 
industry because of the emotional and psychological stigmas that overweight and obese 
individuals face.  Furthermore, due to the sheer number of weight-loss products and diets, 
the potential to use the misalignment of the product and the individual as an excuse for 
the product’s ineffectiveness leads to individuals attempting multiple products before 
either achieving their weight-loss goals or succumbing to the cycle of failure.   
The market for weight-loss products can be divided into two categories based on 
the regulatory constraints established by the government.  The prescription market is a 
highly regulated market that severely restricts the ability for individuals to consume a 
prescription product.  The two regulatory constraints are 1) Firms must establish the 
efficacy and safety of a product prior to marketing to the public, and 2) Firms must abide 
by the FDA’s advertising regulations.  In the prescription market firms also face the 
gatekeeper problem where consumers must ask their physicians for a prescription or the 
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physician must suggest a particular drug for a disease.  Furthermore, pharmaceutical 
marketing over the past ten years (since 1997) has played a critical role in giving patients 
more information about their drug therapy options through the increased use direct-to-
consumer advertising.  Though some have claimed that this growth has placed pressure 
on physicians to tell the patients the reasons for not prescribing a given drug, advertising 
strategies have been focused primarily on telling patients to ask their doctor about a 
certain condition or weight-loss medication.   
The rise in prevalence of obesity has created a new chronic disease, which 
pharmaceutical companies have begun to explore.  Unfortunately, due to the risks 
associated with these products, there is a large debate analyzing the potential benefits of 
these products given the large and sometimes fatal risks.  Although the efficacy debate 
will not be discussed extensively within this paper, the advertising strategies of these 
firms will be analyzed within the scheme of this debate.   
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2. Background Information 
The rising prevalence of obesity has created a demand for weight-loss products.  
With the prevalence of overweight or obesity reaching 70.6 percent in 2003-2004 and the 
prevalence of obesity at 32.2 percent, there is large opportunity for firms to see high 
profits (Ogden et al., 2006).  While the overweight and obesity has substantially 
increased in the adult population, a new and growing concern is the prevalence of 
childhood obesity, which rose to 17.6 percent in 2003-2004 and is a risk factor for adult 
obesity (Ogden et al., 2006).  Individuals who are overweight or obese are predisposed to 
a number of conditions that drive health spending, including diabetes, hypertension, high 
cholesterol, asthma, arthritis, and poor health status (Mokdad et al., 2003).  Each of these 
conditions is extremely expensive and contributes to poor overall health status.  Because 
of the increase in prevalence of overweight and obesity in the past 30 years, Healthy 
People 2010 established goals of reducing the prevalence of overweight and obesity to 15 
percent for adults and 5 percent in children (United States Department of Health and 
Human Services, 2000).  The potential for weight-loss products to reduce the prevalence 
of overweight or obesity has yet to been seen due issues of product safety in both the 
over-the-counter and prescription market. 
The rise in prevalence of overweight and obesity is no longer an individual 
problem, due to the effects on both the economy and the healthcare system.  Recent 
studies have shown that adults who are obese spend on average 36% more on medical 
expenditures than normal weight individuals (Finkelstein, Fiebelkorn, & Wang, 2003).  
Finkelstein et al., (2003) finds that nearly one-fourth of the obese population is sixty-five 
and older and because of the nature of obesity and its co-morbidities this population is 
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more likely to spend at an even higher rate than stated in the figure above.  With such a 
large population of the overweight and obese on Medicaid or Medicare, the costs are not 
borne by the individual, but instead passed through to the taxpayers.  Finkelstein et al., 
(2003) reports, in 2002 approximately half of the costs of obesity is financed by Medicaid 
and Medicare.  In an analysis of excess body weight and the prevalence and costs of 
cardiovascular disease, Wang et al,. (2002) found that of the $181.8 billion spent on 
treating cardiovascular disease in 2001, an estimated $31 billion can be attributed to 
either overweight or obesity.  With the cost of health services due to obesity growing, the 
possibility for weight-loss products to be a solution to this problem has yet to be seen. 
While cardiovascular disease is one of the main diseases associated with obesity, 
some of the others include: type II diabetes, hypertension, gallbladder disease, musco-
skeletal disease, and breast, endometrial, and colon cancer (Visscher & Seidell, 2001).  
While some of these conditions can be treated with proper medications and procedures, if 
the underlying cause is not treated, these conditions may still pose a problem to the 
individual.  With relatively few effective treatments available for treating obesity, the 
need to provide effective preventative measures must be considered (Nestle & Jacobson, 
2000).  Unfortunately, due to the competitiveness of the food industry, advertising of 
healthy behaviors is limited compared to the advertising of food products, which 
accounts $11 billion annually (Nestle & Jacobson, 2000).  While this alone poses a large 
problem, the lack of healthy behaviors and foods advertisements further shifts the balance 
of advertising in the favor of the food industry.  The need to change the behavior of 
individuals must start at a young age as the prevalence of obesity has also affected 
children.  With weight problems now affecting children (18.2 percent of individuals 
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between 2 and 19 classified as overweight), the need to educate children and parents of 
healthy eating behaviors and to promote exercise is becoming essential  
The increase in the prevalence of obesity has allowed for the pharmaceutical 
industry to enter into the market as an effective means of providing individuals with anti-
obesity products in both the prescription and over-the-counter markets (Stafford & 
Radley, 2003).  The recent growth in each market is of interest in this paper as in an 
analysis with specific interest in the advertising of these products.  To date there are nine 
prescription anti-obesity drugs, three of which have been withdrawn from the market due 
to adverse health effects.  Two over-the-counter weight-loss products have had FDA 
warnings released regarding the safety of the product, one of which has been withdrawn 
from the market (ibid).  Due to recent warnings and recalls of both over-the-counter and 
prescription products, this industry has seen a roller-coaster effect in the past few years.  
The apparent safety of these products poses the question: why are people taking these 
medications given the risks of death associated with some of these products? 
Anti-obesity pharmaceutical products are regarded as a complement to diet and 
exercise.  The problem with using solely weight-loss programs is that most individuals 
fail, or lose weight temporarily.  In fact, Polivy (2002) studied the psychology of image 
change and found that most individuals attempt losing weight five or more times before 
they manage a six month success, and of those who fail, 60 percent will make another 
attempt within the next year.  Polivy (2002) also notes that the sheer number of weight-
loss products and programs gives way to a recurring cycle whereby the individual can 
shift failure away from herself and to the weight-loss program by saying the diet was the 
cause of the failure, which leaves the possibility of future successes open.  The number of 
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weight-loss products available in both non-prescription and prescription further 
reinforces this idea.  This recurring cycle is the reason for the need to look at the weight-
loss products market and more specifically the pharmacotherapy market.  The lack of an 
effective means of losing weight makes pharmacotherapy available as an option to 
complement diet and exercise for those who are considered overweight and obese. 
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3. Market for Weight-Loss Products 
In 2000 Meridia (sibutramine hydrochloride) and Xenical (Orlistat) spent a total 
of $100.5 million on DTC advertising ($65.0 million and $35.5 million respectively) 
(National Institute for Health Care Management, 2001).  Xenical and Meridia are the 
only on-patent anti-obesity medications in the market.  The 1997 withdrawal of Pondimin 
(Fenfluramine hydrochloride) and Redux (Dexfenfluramine hydrochloride) due to 
adverse events severely reduced the sales of this therapeutic class of drugs.  According to 
the NIH Care Management (2001), despite spending $65.0 million dollars, Meridia sales 
dropped by 8.1 percent and utilization also dropped 11.3 percent (ibid).  Xenical spent 
$35.5 million and sales rose by 63.8 percent as utilization also rose by 65.1 percent (ibid).  
Due to Xenical’s market entry in April 1999, the cause for the large increase in utilization 
may be explained by a lack of effectiveness and risk information available for physicians 
to make fully rational decisions for their patients (Stafford & Radley, 2003).   
The market for prescription anti-obesity drugs is rather unique in that, according 
to the FDA and the National Heart, Lung and Blood Institute, patients must be clinically 
obese (body mass index > 30 kg/m2) or have a body mass index between 27 and 30 kg/m2 
with an obesity-related comorbidity (i.e. hyperlipidemia, hypertension, diabetes, or 
cardiovascular disease) to be considered for pharmacotherapy (Blanck, Khan, & Serdula, 
2004a; Blanck, Khan, & Serdula, 2004b; Khan, Serdula, Bowman, & Williamson, 2001).  
This requirement limits the number of individuals taking these medications unlike the 
over-the-counter weight-loss products, where there are no usage restrictions.   
In order to analyze the advertising market, the usage of these products is 
necessary to obtain an overall picture to who these firms are targeting.  Cawley and Rizzo 
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(2005) and Blanck et al,. (2004) used data from the Medical Expenditure Panel Survey 
and the 1998 Behavioral Risk Factor Surveillance System Survey, respectively, to obtain 
demographic information on the users of prescription weight loss medications.  In terms 
of race, Cawley and Rizzo (2005) find different prevalences of prescription anti-obesity 
medication usage rates compared to Blanck et al,. (2004).  Cawley and Rizzo (2005) find 
Hispanics were 68.6% as likely to use anti-obesity medication as whites whereas Blanck 
et al,.(2004) found that male Hispanics were 62% more likely and female Hispanics 12% 
more likely to use anti-obesity medication.  Cawley and Rizzo (2005) and Blanck et al,. 
(2004) both found similar results for African American usage, with African American 
anti-obesity drugs usage 51% and 66% of white anti-obesity usage.  Furthermore, Cawley 
and Rizzo (2005) found females were 192% as likely to use anti-obesity drugs  as men, 
which further supported Blanck et al,. (2004).  In terms of education, Cawley and Rizzo 
found that high school graduates were 83.7 percent more likely, those with some college 
are 97.2 percent more likely, college graduates are 104 percent more likely, and those 
with graduate school 141 percent more likely to use anti-obesity than high school 
dropouts.  Finally, Cawley and Rizzo (2005) found that use of anti-obesity drugs 
decreased with rising age.  Use of prescription weight-loss products of those older than 
65 was 46 percent of those between 18 and 29.   
While the growth in the nonprescription weight-loss market has been growing 
over the past ten years, the demographics of users of nonprescription weight-loss 
products mirror that of the prescription anti-obesity products.  According to Blanck et al,. 
(2001), females were 4.9 times more likely than males to use these products between 
1996 and 1998.  Furthermore, usage among African Americans and Hispanics was 90 
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percent of the usage among whites in this sample.  The nonprescription market was 
similar to the prescription market with education level in that individuals with a high 
school diploma were 50 percent more likely to use nonprescription products than those 
with less than a high school diploma.  Continuing the similarities between the 
nonprescription and the prescription market individuals with some college or with a 
college degree or higher were 80 percent and 50 percent more likely to use 
nonprescription products than those with less than a high school diploma respectively 
(Blanck, Khan, & Serdula, 2001).  The usage of nonprescription weight-loss products is 
lower for college graduates mainly because these individuals are more likely to see a 
physician and consequently prescription weight-loss products.  In terms of age, 
individuals between 18 and 34 were 50 percent more likely to use the product than 
individuals between 35 and 54.  Individuals who were 55 and older were 60 percent less 
likely to use nonprescription weight-loss products than individuals between 35 and 54.   
This demographic information about the users of both prescription and 
nonprescription weight-loss products is vital for advertising of weight-loss products.  
This information allows the pharmaceutical industry to develop targeted marketing 
campaigns that will help firms maximize their profits by reaching the population most 
likely to buy and use these weight-loss products.   
Safety Regulation of Weight-Loss Products 
The determination of the safety of these pharmaceutical drugs varies depending 
on its classification as either over-the-counter or prescription.  Prescription products 
undergo a rigorous set of trials before they ever reach the market for sale to the 
consumer.  The firms of over-the-counter products face relatively looser regulations.  In 
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the next two paragraphs, the regulations constraining these firms will be further explained 
for both the over-the-counter products and prescription products. 
The regulations for determining the safety of over-the-counter weight-loss 
products have changed drastically as a result of the Dietary Supplement Health and 
Education Act of 1994.  This act created two classes of weight-control products.  The 
first class of products requires pre-market approval from the FDA to determine safety and 
is considered non-dietary supplements.  The second class consists of dietary supplements 
intended for weight control.  This class is not subjected to pre-market approval.  Because 
dietary supplements are not subjected to pre-market approval, there has been a dramatic 
increase in the number of dietary supplement weight loss products.  This increase has 
been paralleled with an increase in the amount of weight-loss product advertising, with 
over 280 nutritional support statements filed for dietary supplement products with the 
FDA claiming weight-loss benefits between January 1996 and August 2001 (Cleland, 
Gross, Koss, & Muoio, 2002).   
The process for market approval of prescription products is an extremely costly 
and time-consuming process that requires three stages of pre-marketing clinical testing 
before approval by the FDA.  Phase 1 trials are generally small trials conducted on 
healthy individuals in order to assess the safety, metabolism, and response of the new 
drug.  Phase 2 trials analyze the effectiveness of the drug for a particular indication or 
indications in patients.  This phase assesses the efficacy of the drug on a specific disease 
or condition.  Phase III clinical trials are the final pre-marketing phase before drug 
approval.  Phase III trials occur on the largest scale usually involving several hundred to 
several thousands of subjects.  Once all three phases of clinical trial data are conducted, 
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the pharmaceutical firm must submit a New Drug Application (NDA) with the Center for 
Drug Evaluation and Research within the FDA.  Upon receiving the NDA, the FDA has 
60 days to respond, to decide if the information regarding the clinical trial data is 
sufficient to conduct a review of the drug.  Following the review, the FDA can decide 
whether to approve the product for the market or declare that the agency would approve 
the drug after further testing regarding effectiveness or safety.  The costs of bringing a 
prescription weight-loss product to market are much larger than for over-the-counter 
products.  As a result, there are fewer prescription products available on the market 
(Schweitzer, 2007). 
Risks associated with weight-loss products 
The over-the-counter weight-loss product market is regulated by the FDA for 
product safety and the FTC for advertising of these products.  The FDA has classified the 
two active ingredients, ephedra and phenylpropolamine (PPA), unsafe.  Ephedra and 
phenylpropolamine have been used historically in most over-the-counter weight-loss 
products.  These two ingredients differ in their classification according to the FDA.  
Ephedra is not considered an over-the-counter drug like PPA, but is considered a dietary 
supplement and thus falls under the 1994 Dietary Supplement Health and Education Act 
(Blanck et al., 2001).  Under this act, the manufacturer is responsible for determining 
whether a product is unsafe rather than the FDA.  The FDA proposed restrictions on 
products containing Ephedrine alkaloids in June 1997 (ibid).  The major problem with 
Ephedra is that it increases the risk of cardiovascular (myocardial infarction) and 
cerebrovascular (cerebrovascular accidents, seizures, and hemorrhagic stroke) disorders, 
which accounts for 140 reports of adverse events between June 1997 and March 1999 
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(Allison et al., 2001; Morgenstern et al., 2003; Shekelle et al., 2003).  Between June 1997 
and March 1999, 140 reports of adverse events related to ephedra products were filed 
with the FDA (Blanck et al., 2001).  Without adequate medical supervision, the use of 
ephedra-containing products can cause severe medical problems that can lead to death.  
The FDA’s warning was withdrawn in April 2000 after the General Accounting Office 
concluded that additional evidence was needed to support these restrictions, but the FDA 
recommended a labeling statement that instructed users to consult their physician prior to 
use.   
The second product, phenylpropolamine, falls under the classification as an over-
the-counter drug and thus faces different regulations compared to ephedra products 
(Blanck et al., 2001), though PPA is chemically related to ephedra ((Clapham, Arch, & 
Tadayyon, 2001).  PPA was considered a safe weight reduction agent until recently, 
although reports of adverse cerebrovascular and cardiac events were reported earlier.  It 
was not until a study by Kerman and colleagues (2000) found that PPA increased the risk 
of hemorrhagic stroke that the danger was recognized.  For females, an odds ratio of 
16.58 was found for the association between the use of appetite suppressants containing 
PPA and the risk of a hemorrhagic stroke.  For men and women combined the risk of a 
stroke when using appetite suppressant PPA was 15.92(Kernan et al., 2000).  With this in 
mind, all of the over-the-counter PPA products were voluntarily withdrawn from the 
market in November 2000 (Blanck et al., 2001)1. 
                                                 
1 PPA is also found in other products such as cough and cold remedies.  Kerman and colleagues (2000) 
found an odds ratio of 1.23 (95 percent confidence interval, 0.68 to 2.24), which was not statistically 
significant.  Despite the lower risk of hemorrhagic stroke for the use of cough and cold remedies, the FDA 
chose to remove all over-the-counter PPA products given the risk of such an event (Blanck et al., 2001).   
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The safety of these over-the-counter weight-loss medications will constantly be in 
question, given the current regulations to determine safety for dietary supplements.  But 
even with the FDA’s oversight, the risks of adverse events exist with the use of anti-
obesity drugs.  Of the nine prescription drugs available on the market, three have been 
withdrawn from the market due to risks of heart valve abnormalities and pulmonary 
hypertension.  Because the risks of heart valve abnormalities was seen as a temporary 
side effect that had the potential to reverse itself, the use of fenfluramine and 
dexfenfluramine were seen as temporary medications for the treatment of obesity 
(Shively, Roldan, Gill, Najarian, & Loar, 1999).  According to Gardin and colleagues, the 
users of dexfenfluramine are older, more obese, more hypertensive, and have more 
history of cardiovascular disease than the general population.  Considering the overall 
population of the users of these products, the risk of pulmonary hypertension or heart 
valve abnormalities can be fatal.  While fenfluramine and dexfenfluramine are considered 
potentially fatal products, two drugs have recently been released with some potentially 
serious side effects since the withdrawal of fenfluramine and dexfenfluramine in 
September of 1997.   
The release of sibutramine (Meridia) and orlistat (Xenical) in November 1997 and 
April 1999, respectively, has allowed for some minor recovery in sales for the 
prescription anti-obesity market, but according Staffard and Radley (2003), the usage is 
still not as large as it was in 1996, the year before the withdrawal of dexfenfluramine and 
fenfluramine.  For the most part sibutramine has relatively mild adverse effects including, 
headaches, dry mouth, constipation, insomnia, rhinitis, and pharingitis.  Unfortunately, 
the major adverse effects for patient withdrawal from most clinical studies were due to 
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hypertension caused by the medication.  Sibutramine increases blood pressure by 1-3 mm 
Hg patients (Halpern & Mancini, 2003).  This increase in blood pressure has the potential 
to be a severe problem especially for patients who have uncontrolled hypertension.  
Consequently, the use of this drug counteracts the potential benefit of weight-loss by 
preventing the fall in blood pressure (Bray, 2001).  As a result of the potential increase in 
blood pressure sibutramine is contraindicated for patients with a history of hypertension, 
coronary artery disease, congestive heart failure, cardiac arrhythmias, or stroke.   
Orlistat, on the other hand, has adverse effects on the digestive system and its 
ability to absorb nutrients.  The major side effects are related to the inability to digest 
triglycerides in the intestines, which also prevents the absorption of fat-soluble vitamins 
(ibid).  The other adverse events included a higher incidence of diarrhea (relative risk, 
3.40), flatulence (relative risk, 3.10) and bloating, abdominal pain and dyspepsia (relative 
risk, 1.48) when compared with control groups.   
The risks of using either weight-loss drugs or anti-obesity drugs can be severe, 
and yet this market still appears to prosper.  With the success rate of weight-loss being 
relatively low, firms view the market for weight-loss products extremely promising.  
Given the large number of over-the-counter products on the market, the need to advertise 
these products has become necessary to maximize profits.  The methods used by firms to 
maximize utilization of these products through marketing presents some interesting 
questions:  What elements of persuasion does the pharmaceutical industry use in their 
marketing campaigns to physicians and patients respectively?  How does the 
pharmaceutical industry react to changes in advertising regulations?   
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4. Economic Framework 
Under traditional economic theory, pharmaceutical firms make decisions based on 
the conditions of the market in an attempt to maximize profits.  Advertising has become 
an option for firms to increase the recognition of their product in an attempt to increase 
the consumption of their products and profits.   
In this paper, advertising by firms producing over-the-counter weight-loss 
products will be analyzed by a two-player sequential game.  Because the firms are 
restricted to a set number of products (meaning it is impossible for these firms to change 
their product within a given period of time), the firms (the first player) must choose an 
advertisement to maximize their profit.  As a result of these advertisements, the 
consumers (the second player) choose a product, and thus the firms receive profits.  In 
order to maximize profit, the firms must choose the advertisement that compels 
consumers to purchase their products and thus maximize their profit.   
Although the desired goal of maximizing profits is shared by both the prescription 
and over-the-counter market, the economic framework underlying the advertising of 
products in the prescription market is more complex.  The prescription market can be 
described as a three player market involving the firm, the consumer, and the physician.  
In this market, firms must choose advertisements that are effective at compelling 
physicians to prescribe their product.  The firms of prescription products do not have to 
encourage a potential consumer to purchase the product because the average consumer 
cannot purchase a prescription product.  Instead, the consumer must visit their physician 
in order to obtain a prescription for the desired product.  Consequently, these firms have 
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to encourage consumers to ask their doctor about the product.  Thus, the physician makes 
the final decision to use a given medication. 
Based on the two- and three-player sequential games, the firms are constrained by 
the market regulations, which limit their ability to advertise freely.  The first constraint 
that exists in this market is the advertising regulations.  Under the 1962 amendment to the 
Food, Drug, and Cosmetic Act, the regulation of advertising prescription products was 
transferred from the FTC (still regulates the advertising of OTC products) to the FDA, 
resulting in differing advertising regulations for each market (Calfee, 2002).   
Advertising of over-the-counter weight-loss drugs and dietary supplements fall 
under FTC jurisdiction.  Under FTC regulations, there are two basic principles of 
advertising: 1) the advertisement must be truthful and not misleading and 2) prior to 
releasing the advertisement, the distributing company must have adequate substantiation 
of all objective product claims.  Section 5 of the FTC Act finds unfair or deceptive acts or 
practices unlawful.  Deceptive advertisements pertaining to foods, drugs, devices, or 
cosmetics is further prohibited in Section 12 of the FTC Act.  Under these clauses, 
deception may be presented with the presence of false or misleading information, or the 
omission of information that affects the consumer’s conduct or decision making ability 
(FTC Policy Statement on Deception).  Along similar lines, the expected level of 
substantiation of these advertisements also helps reduce deceptive claims.  Under the 
Federal Trade Commission Act (104 F.T.C. 648, 839 (1984)), the advertisement must 
provide at least a “reasonable basis” for its claims if there is no express or implied 
reference or evidence indicating consumer expectations.  According to the FTC, 
“reasonable basis” depends on: the type of claim, the product, the consequences of a false 
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claim, the benefits of a truthful claim, and the cost of developing substantiation for the 
claim and the amount of substantiation experts in the field believe is reasonable.  With 
such a broad definition for substantiation, the over-the-counter and dietary supplement 
weight-loss products have, in some ways, very little restrictions in their claims as long as 
they are able to meet this broad standard of “reasonable basis.”    
Prescription drug advertising directed at both physician and consumers is more 
complex than over-the-counter drug advertising.  Currently, there are four main FDA 
regulations overseeing product claims advertisements.  Under these regulations, the 
product claims for print advertisements: 1) cannot be false or misleading; 2) must present 
a fair balance between risks and benefits; 3) must present facts that are relevant to the 
representations made in the advertisement or the consequences of using the product as 
advertised; and 4) must disclose all the risks in a product’s label (21 U.S.C. 352(n))2.  
Similar to the over-the-counter and dietary supplement advertisements, the direct-to-
consumer prescription advertisements must present no false or misleading information 
and the information must be consistent with the product label.  The prescription 
advertisement regulation differs in the requirement of “fair balance.”  The concept of fair 
balance requires that both risks and benefits be clearly used throughout the advertisement 
(ibid).  The third main requirement of print product claim advertisements is that the facts 
released in the advertisements are understandable to the public, and that the consequences 
of use are clearly described.  This is important because without clear consequences of the 
product, false or deceptive advertising becomes potential possibility for regulatory action 
taken against the firm.  The fourth requirement is possibly the most important and costly 
for these all firms advertising prescription products.  The inclusion of all the risks in a 
                                                 
2 21 U.S.C. 352 (n) – FDA Regulatory Policy regarding Advertising of Prescription Product 
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product’s label has resulted in the requirement of an additional page of a “brief summary” 
of all the risk information that includes contraindications, side effects, and effectiveness.   
These regulations alter the behavior of the firms by increasing the cost of 
advertising for the prescription products relative to OTC products.  Firms must decide the 
length of the advertisements and the information, images, and social themes disseminated 
to the consumer while still complying with these regulations.  The current literature 
categorically classifies the information and themes in advertisements in order to 
conceptualize and code the way information is disseminated to the consumer.  On the 
most basic level is the dissemination of effectiveness and side effects of using the product 
and disease and symptom information (Bell, Kravitz, & Wilkes, 2000; Calfee, Winston, 
& Stempski, 2002; Gilbody, Wilson, & Watt, 2005; Roth, 2003; Wolfe, 2002; Young & 
Welch Cline, 2005).  Firms can also use motivational claims to further increase the 
consumption of their products.  The literature classifies the motivational claims into two 
categories: Informational and Transformational.  Informational claims are negative and 
are undesired end-states, whereas transformational claims are positive and are desired 
end-states.  Firms also have the ability to depict social images through the use of models, 
which varies based on the target audience of the advertisements (Bandura, 2001).  Social 
cues have the ability to change the consumers’ perception of a product.  The current 
literature on advertising of drug products uses social cognitive theories to analyze the 
way individual interpret each of these attributes disseminated within advertisements.   
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5. Literature Review 
Pharmaceutical advertising is identical to all other forms of advertising and thus 
faces the problem of attracting a consumer base.  Two social cognitive theories provide a 
framework for analyzing the content of advertisement on its ability to change behavior: 
Petty and Cacioppo’s (1983) Central and Peripheral Routes model and the Bandura’s 
(2001) Social Cognitive Theory of Mass Communication.  Although these two theories 
were created as a way to analyze the effectiveness of advertising in general, the nature of 
pharmaceutical products and the recent increase in direct-to-consumer drug advertising 
has allowed for a new application of these theories due to the differing nature of these 
products.   
The central and peripheral routes model is a social cognitive theory that relates to 
the involvement of the individual (the relevance of the product to the individual) and the 
mechanism that causes an attitude change.  Petty and Cacioppo (1981) explain that the 
individual’s involvement when viewing an advertisement is essential to changing an 
individual’s attitude about the product.  In the context of weight-loss products, Petty and 
Cacioppo’s theory explains that an individual looking to lose weight will be more likely 
to respond to an advertisement than an individual who is not looking to lose weight (Petty 
& Cacioppo, 1981).  While involvement is a key determinant of attitude change, the way 
an individual interprets the advertisement is also important.  Petty, Cacioppo, and 
Schumann (1983) explain in their model that two routes affect attitude change: the central 
route and the peripheral route.  An attitude change that occurs under the central route 
usually occurs after an individual has considered all the information she feels relevant to, 
in this case, the use of a weight-loss product.  This route in most cases usually requires a 
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unique interest (high involvement) to the individual because of the amount of effort 
needed to process all the relevant information.  Conversely the peripheral route causes an 
attitude change, not because the individual has considered the pros and cons of using the 
product but because something within the advertisements elicits a positive or negative 
cue (Petty, Cacioppo, & Schumann, 1983).  Petty and Cacioppo (1981) provide the 
example of a person who uses Hertz Rent-a-Cars not because she has diligently 
considered each aspect of the company, but because she is constantly reminded that O.J. 
Simpson was in its advertisements.  Consequently, based on the social cognitive theory of 
involvement and central and peripheral routes, the use of imagery in the advertising of 
weight-loss products may provide a more effective means of providing an attitude change 
than the use of textual claims (Petty & Cacioppo, 1981).   
Bandura (2001) on the other hand describes the effect of social cognitive theory 
with respect to mass communication and how individuals react to the information.  The 
model explains there are four processes that occur as a result of this form of 
communication: attentional process; retention processes; production processes; and 
motivational processes.  Each process governs how the individual learns through 
observation and ultimately, how individuals will change their behaviors as a result of 
observing the social interactions presented in the advertisements (Bandura, 2001).   
The simplest process is the attentional process, which determines what 
information is taken from an advertisement.  Factors like salience, attractiveness, 
prevalence, and functional value to the individual are usually the main predictors that will 
affect observational learning.  The attentional process is necessary for an individual to 
transform and restructure the information in order to retain the information as a memory.  
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Retention involves the ability to structure the conveyed information into memories, usual 
symbolic memories.  This form of cognitive organization allows the individual to recall 
the information from the advertisement, which is essential for determining the 
effectiveness of the advertisements.  But recalling an advertisement does not always 
mean that the individual will purchase the product.  The production processes occurs 
when these symbolic memories are translated into appropriate course of action.  The 
behavioral production processes is the ability to transform the symbolic memory into 
behavior patterns that are called for by the advertisements (Bandura, 2001).  With respect 
to weight-loss products, this process would be to either begin an exercise regimen, diet, 
or medication in an attempt to lose weight.  The behavior does not need to be performed, 
but the formalization of a “course of action” in response the advertisement must occur.  
The final process that Bandura (2001) identified is the motivational processes.  
Because individuals do not always perform everything that they learn, the motivational 
processes distinguish between acquisition of information and the performance of an 
observationally learned behavior.  With respect to weight-loss, this motivational 
processes explains how individual are motivated by the successes of others similar to 
them, but are discouraged by the adverse consequences of failing (Bandura, 2001; Polivy 
& Herman, 2002).  The effectiveness of advertisements ultimately depends on the firm’s 
ability to alter the behavior of the individual.  In the case of weight-loss products, the 
firms must differentiate their product from their competitors in order to profits through 
increasing brand name recognition.   
These two social cognitive theories are necessary to fully describe the current 
literature’s conceptualization of advertisement attributes.  Throughout the review of this 
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literature and the analysis of the data, these social cognitive theories have the ability to 
begin explaining consumer behavior in response to firm advertising methods.   
The most basic but most important aspect of weight-loss product advertising is the 
disclosure of drug effectiveness and the side effects.  With the withdrawals of Redux, 
Pondimin, and PPA, the disclosure of side effects and adverse events has become an 
important aspect to consider.  Prescription advertisements must present a fair-balance of 
information in the advertisements (Palumbo & Mullins, 2002; Pines, 1999).  The 
presentation of the drug effectiveness and risks is regulated by the FDA, and according to 
Roth (2003), Beltramini (2006), and Mehta and Purvis (2003), the effectiveness of this 
information in changing behavior often times lies in the believability of the information 
presented.  Beltramini (2006) explains that the believability of the information is often 
times more important than the understanding of the information in determining the desire 
to use that particular drug.  Although the pharmaceutical industry relies on the 
believability of these advertisements, the FDA looks primarily at the balance of the 
information of risks and benefits and the truthfulness of the advertisement.   
Few studies looked at the balance of information in advertisements, Young and 
Welch Cline (2004) in their analysis of the textual cues of 994 DTC advertisements 
found, the ratio of medical rewards to medical punishments to be 4.3 to 1.  Young and 
Welch Cline found that most textual cues were used to promote the product’s 
effectiveness, general claims of effectiveness, and the punishing effect of not using the 
drug, rather than the negative effect of not using the drug (Young & Welch Cline, 2005).  
Furthermore, all of the advertisements with exceptions of advertisements for HIV/AIDS 
drugs, contained information of specific claim effectiveness, whereas only 50.7 percent 
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of the advertisements contained at least one medical punishment message (side effects 
and/or risks).   
Although Young and Welch Cline (2004) analyzed the claims specific to the 
promotional claims, the dissemination of side effect information to the consumer via 
these advertisements has been analyzed in Davis (2000).  Davis (2000) experimentally 
tested the effects of incomplete risk statements.  Davis (2000) found that when presented 
with incomplete side effects the individuals disproportionately chose to purchase the 
product than when presented with a complete risk statement.  The need to analyze the risk 
and benefit statements in these advertisements is essential for the weight-loss market 
especially given the risks and side effects of this class of drugs.  The benefit information 
available in these advertisements largely outweighs the risk information in most drug 
advertisements and must be considered when analyzing the advertising market for 
weight-loss drugs and analyzing firms’ adherence to advertising regulations.   
The use of disease information is essential for the targeting of specific 
populations.  Many supporters of DTC advertising claim that advertising both increases 
the awareness of certain diseases and also the available treatments as individuals highly 
involved in the management of their health will respond to these advertisements ((Calfee, 
2002; Shah, Holmes, & Desselle, 2003; United States. Gen. Accounting Office., 2002; 
Welch Cline & Young, 2004; Wilkes, Bell, & Kravitz, 2000).  Roth (2003) analyzed the 
effectiveness of print advertisements on consumer awareness and found in his analysis of 
208 unique DTC prescription advertisements that the frequency with which DTC 
advertisements used disease and symptom information was 42.7 and 61.5 percent 
respectively.  Additionally, he also found that advertising awareness was higher when 
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symptom information was not conveyed (B = -0.203, p <0.01).  The inclusion of disease 
and symptom information did not increase brand awareness but instead decreased it.  
Petty and Cacioppo (1981) explain that this may be due to the inclusion of too much 
information in the advertisements resulting in the use of the peripheral route or the use of 
other visual and textual cues to make their decision rather than a systematic analysis via 
central route.  The disease and symptom information is essential for the proper behavioral 
modification as described by Bandura (2001), yet in the prescription market, the 
individuals must still consult their physician before they are prescribed the medication.  
Consequently, the disease and symptom information may not be essential for DTC 
advertising, but it appears to be essential for informing physicians of the drug.   
The information provided to consumers has been somewhat criticized by 
physicians and policymakers in that it has been contributing to the rise in healthcare 
costs.  As described by Roth (2003), the presence of disease and symptom information 
does not increase the recall of the advertisement, but instead decreases recall.  As a result 
many studies have questioned the effectiveness of the DTC advertisements as an 
educational tool that consumers can use to understand their conditions (Calfee, 2002; 
Gilbody et al., 2005; Wolfe, 2002).  Gilbody et al., (2005) conducted a literature review 
that analyzed the current studies that have been performed on the impact of direct to 
consumer advertisements.  They found an increased burden on the physician to correct 
the patients’ desires and explain the correct course of action.   
The nature of the disease and symptom information presented in the 
advertisements varies drastically between markets.  The information provided in 
physician-directed is more clinically based and acts as a form of education for the 
Gong 29 
physicians.  According to Fisher (2003), there has been a growing use of advertisements 
because they are more visually stimulating and more accessible than papers in medical 
literature (Fisher, 2003).  The ability for the pharmaceutical companies to frame the 
information in the clinical studies plays a large role in the decisions for the prescribing of 
the drug.  The ability for a manufacturer to cite clinical studies in advertisements to 
physicians has the potential to improve sales. 
While the use of textual cues through the inclusion of disease, symptom, benefit, 
and side effect information is necessary to promote the benefits of usage, the motivational 
aspects of advertisement is sometimes considered the most important and influential 
aspect that will determine the consideration of a product.  In the literature review, 
motivational cues come across with a few different definitions.  Roth (2003) claims that 
there are two types of motivations that are presented in advertisements: informational and 
transformational motivations.  Informational motives tend to refer to consumer’s 
experiences of events that tend to be avoided and considered undesirable.  
Advertisements that present informational motives usually use problem removal or 
problem avoidance images.  Transformational advertisements tend to present positive 
images and “desired end states” (Roth, 2003).  Young and Cline (2005) analyze what 
Bandura (2001) described as direct and vicarious motivational cues.  These two cues 
recognize the idea of identity and relational goals of the drug.  In both cases, with respect 
to weight-loss products, the advertisements will use images of individuals’ with perfect 
bodies or individuals who seem content with their body image, which can be considered 
the “desired end state” or “identity and relational goals” for individuals looking to lose 
weight.   
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Roth (2003) found that 81% of their sample used informational messages, while 
19% contained only transformational messages which were consistent with past research 
(Pinto, 2000).  But Roth (2003) also found that transformational cues were associated 
with higher brand awareness when compared to informational cues.  While informational 
messages were used 81% of the time, the focus of this study looked at an aggregate of all 
the direct-to-consumer advertising, rather than just one therapeutic class of drugs.  A 
further analysis of the therapeutic classes analyzed in this study reveals that 
antihistamine, anti-inflammatory, and asthma and respiratory medications accounted for 
27.9 percent of the sample.  The advertising of these products differs greatly from the 
advertising of weight-loss medications, which may result in some differing use of these 
two types of messages.   
Due to the nature of over-the-counter drug advertisements, the way individuals 
use information is not entirely straightforward.  With over-the-counter advertising, the 
information provided tends to be less scientifically-based and more describing or 
showing the desired outcomes of the individual using the product.  Consequently images 
of perfect bodies or dramatic weight-loss stories are more prevalent in this class of 
advertisements.  The nature of the over-the-counter drug advertising market significantly 
differs in the methods of appeal because of the nature of the advertisements.  The use of 
less scientifically-based information and more images of desired end states will motivate 
certain consumers in unique ways based on their interest levels.  According to Petty and 
Cacioppo’s ELM model, the use of scientific information is a highly-involved process for 
individuals to comprehend and understand and thus the use of scientific information 
would elicit a response from only the high-interest levels.  The ELM model further 
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explains that the use of images is a less involved process, which means these 
advertisements would gain a response from a broader audience of viewers.   
The overall social depiction within the advertisement is an interesting aspect to 
analyze.  The use of social cues has been one of the most interesting advertisement 
appeals because of its ability to capture the attention of the consumer.  Two models can 
explain how the use of social cues affect the way a product is remembered.  Schooler, 
Basil, and Altman (1996) analyze the social cues on billboard advertisements of tobacco 
and alcohol products.  The presence of the negative aspect of tobacco and alcohol 
products have been well substantiated given the surgeon general’s warnings as well as 
public service announcements, but the social cues presented could potentially shift the 
attention away from these risks and to potential benefits (Schooler, 1996).  In addition to 
the social cues, the consumer’s ability to relate with the advertisement improves the 
effectiveness, which usually results in firms attempting to align the ethnicity, gender and 
social environment of the models with that of the target audience.  Schooler, Basil, and 
Altman (1996) also note the attractiveness of the models plays an important role.  Priester 
and Petty (2003) contend that the spokesperson or endorser trustworthiness plays a large 
role on the advertisement’s effectiveness as well as the retention of the information 
presented in the advertisement.  The final aspect of social cues is the rewards.  Images of 
romance, friendship, vacationing, active lifestyles, and adventure were used commonly to 
show that this product could change their life.   
The social depiction is essential to most advertisements in this market.  Given the 
potential positive effects of the use of these products on the individuals, in terms of 
weight loss, the images provided in these advertisements are one of the most important 
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aspects of these advertisements.  In some respect, the presence of the social depiction has 
the potential to reduce the importance of the side effects and elicit a response based on 
the positive transforming effects of the product.   
While these studies look to analyze a specific attribute of prescription print 
adverting, this study analyzes the visual and textual cues for both prescription and over-
the-counter weight-loss products.  With the large number of adverse events reported 
within this class of drugs, the need to analyze the type of claims in these print 
advertisements is necessary to understand why people are using these products, with the 
possible risk of death.   
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6. Hypotheses 
H1: Firms will choose to place advertisements in magazines targeted toward female 
readership magazines and thus will portray women more frequently than men.  In 
addition to the gender differences in the target audience, firms will also advertise in 
magazines with higher white female readerships and will portray more white 
women than African American or Hispanic women.   
The growth of the direct-to-consumer advertising for weight-loss products has 
come at a time when weight-control practices among U.S. adults is influenced 
predominantly by women.  The media has developed this image of an ideal body size, 
which has unfortunately become the target of most women.  Weiss, Galuska, Khan, and 
Serdula (2006) found that 47.9 percent of women tried to lose weight during 2001 and 
2002 compared to 33.8 percent of men.  Meanwhile, the usage rate of weight-loss 
products predominantly favors white women over every other group.  In light of this 
information, firms will maximize the effectiveness of their advertisement by targeting a 
specified audience, which has been based largely upon Bandura (2001) and Petty and 
Cacioppo’s (1981) social cognitive theories.  
These two social cognitive theories explain how consumers react to 
advertisements based on the relevance of information provided.  Bandura (2001) explains 
in his social cognitive theory of mass communication that the effectiveness of an 
advertisement can depend on whether the individual can identify with the advertisement.  
This model explains that the ability for an advertisement to initially captivate the 
consumer will determine the effectiveness of the advertisement.  Under this model, this 
ability usually depends on whether the individual can identify with the advertisement.  
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This model is similar to Petty and Cacioppo’s (1981) theory of high and low 
involvement.  Petty and Cacioppo differ in that they analyze consumer based upon 
involvement or interest levels.  The higher a consumers interest level in a product, the 
higher the likelihood that the consumer will act upon the advertisement.  Knowing that 
individuals respond based upon their interest level, firms will react by targeting certain 
populations.  In this case, we expect focus of advertisements in magazines with 
predominantly white female readerships. 
H2: Prescription advertisements will include fewer images of individuals and will 
use more information when compared to the over-the-counter products due to the 
differing advertising regulations.  
Despite the lack of research comparing the effects of differing advertising 
regulation, there is a division in the way a product is portrayed based on its classification.  
The FTC’s regulations are less stringent than the FDA prescription regulations and thus 
portray the transformative power of these advertisements.  As Roth (2003), Young and 
Welch Cline (2004), and Welch Cline and Young (2005) cite the use of “desired end” 
states are better in improving product recognition.  Furthermore, Petty and Cacioppo’s 
(1983) central route and peripheral route processing explain the social cognitive approach 
to the reasoning for using these types of visual cues.  The use of models and before and 
after pictures would elicit a peripheral route response because consumers would 
remember the product for its weight-loss effectiveness rather than information 
disseminated within the claims.   
The FDA regulations constrain the prescription market by mandating the 
disclosure of all the risk and the presence of a fair-balance of information (risks and 
Gong 35 
benefits must be disclosed in a balanced manner) (21 CFR 202.1).  While these 
regulations have a significant effect on the claims made within the advertisement the 
target audience also differs based upon the users of the drug.  In order to use a 
prescription weight-loss product, you must have a BMI over 30kg/m2.  This drastically 
hinders the firms’ ability to use individuals because the individuals within the 
advertisement must be overweight or formerly overweight to be seen .   
While in our analysis we do expect to see more individuals within the OTC 
product advertisements, we are also expecting a substantial difference in the clothing 
presented within the advertisements.  Based on the previous paragraph, the fact that 
individuals must have a BMI over 30kg/m2 to be considered as a potential patient for this 
product, we expect the prescription advertisements to use only athletic clothing, casual 
clothing, or professional/dress up clothing.  The ability use of individuals having a BMI 
over 30kg/m2 would not be aesthetically appealing and would not display the true 
effectiveness or intent of the product.  Conversely, because there are no constraints on the 
individuals taking the OTC products, these firms would use more individuals wearing 
bathing suits or athletic clothing to show the “desired end” state of using the product.  
While the use of bathing suits and athletic clothing to some degree show a “desired end 
state,” they do reveal differing cues to the public.  The bathing suits tell the consumer that 
she will feel comfortable with her body image through taking this product, whereas the 
athletic clothing motivates the consumer to become more active.  Ultimately through 
using images of relatively fit and good-looking individuals, consumers will remember the 
advertisements not for the claims it makes, but more for the potential effectiveness of the 
product.   
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While the use of attractive individuals tells us what type of visual messages the 
firms are sending to the advertisements, the nature of the advertisement appeal will 
provide us with the most influential appeal of the advertisement.  The regulations for the 
advertisements of prescription products will constrain the firms’ behavior and result in a 
smaller variance of advertisements focused around dissemination of risk and benefits.  
Conversely, the OTC product advertisements will have a wider variation of claims 
ranging from sexual appeal to anecdotal claims because of the differing advertising 
regulations. 
H3: Advertisements directed toward physicians will contain more clinical trial data 
than the consumer directed advertisements.  Furthermore with regards to the 
dissemination of risks, physician advertisements will contain more risks within the 
body of the advertisement than the consumer advertisements.   
We hypothesize that because physicians are more knowledgeable and rely more 
on scientific data, the physician directed advertisements will contain more clinical trial 
data and actual effectiveness statistics than direct-to-consumer advertisements.  
Conversely, because the consumers are generally less scientifically informed about their 
conditions, we expect consumer-directed advertisements to use personal anecdotes and 
general effectiveness summaries as opposed to effectiveness statistics.  Based on Petty 
and Cacioppo’s theory, the use of too much information has a negative effect on memory, 
unless the individual is comfortable with the information.  This means that an 
advertisement with too much or too complex information will cause an individual to 
become confused and forget the advertisement.  Roth (2003) confirms this notion when 
he finds that as a firm decides to include more disease and symptom information an 
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advertisement, the consumer is less likely to recognize or recall the advertisement or 
product name.  Consequently, as the amount of information increases the consumer will 
use the central processes up until the point where the consumer becomes confused or 
disinterested and then the peripheral processes takes over.  The individual will remember 
an advertisement with too much information for its images and headlines rather than the 
actual details of the product. 
The presentation of risk information will be different throughout the 
advertisements.  Firms acknowledge the behavior expected of their targeted audience and 
consequently present the risks differently.  For physicians, we expect the firms to present 
the risks in a manner that promotes the safety of the product.  While for consumers, the 
firms will only disseminate the major contraindications and side effects within the main 
text of the advertisement.  Firms realize physicians sometimes rely on these 
advertisements for information, and consequently we expect more risks disseminated in 
the main pages of the advertisement in physician advertisements compared to direct to 
consumer.  All of the risks are expected to be found in the advertisement in the directives 
page if they are not stated in the main text of the advertisements. 
H4: Advertisements for over-the-counter drugs will present more benefit 
information and less risk information than DTC advertisements of prescription 
drugs.  
Because of a lack of fair-balance clause (meaning the advertisement can not just 
present the benefits) in the FTC regulations, we expect to see over the counter firms to 
promote only their products’ benefits and fail to inform the consumer of the risks 
associated with using the weight-loss product.  While the FTC and the FDA agree that 
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advertisements must present products in a non-deceptive or non-misleading way, the 
FDA’s regulation requiring a “fair balance” of information in the advertisement and the 
mandatory inclusion of a brief summary page imposes a restriction on the firms thus 
leading to longer advertisements containing more risk and benefit information.  We 
expect firms to include both benefits and risk information in the DTC advertisements of 
prescription weight-loss products.   
H5: After the withdrawal of weight-loss products the pharmaceutical companies will 
try to advertise the benefits of their remaining over-the-counter products in 
comparison to those that were withdrawn from the market due to adverse side 
effects (or subjects of warnings).   
Due to the withdrawal of PPA in the over-the-counter market, we expect each 
market will react by advertising or differentiating their product from these withdrawn 
products to gain market share.  For the over-the-counter market, we expect to see drugs 
marketed saying they do not contain PPA.  A similar marketing campaign may be seen 
for ephedra given the safety warnings released in 1997 saying ephedra was linked to 
some heart conditions and even death.  Because Redux and Pondimin affect heart valves, 
we expect claims from Meridia and Xenical that their products do not affect heart valves.   
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7. Data and Methods 
This paper uses the SCADS database for direct-to-consumer advertisements and 
physician directed advertisements of over-the-counter and prescription weight-loss 
products from January 1997 to July 2002 systematically collected from 19 of the most 
popular magazines in the market (See Appendix 2 for a description of the SCADS 
database and the magazines) and two medical journals.  The physician directed 
advertisements were taken from the two most popular medical journals, the Journal of 
American Medical Association and the New England Journal of Medicine from the years 
1997 to 2002.  Unfortunately, the collection of advertisements taken from the Journal of 
American Medical Association are incomplete because the libraries bound the copies of 
the Journal of American Medical Association were missing the “Demographic and 
“Mini” inserts an/or ROB ad pages.”  However, the occurrences and length of each 
advertisement were within the same time frame of publication and length to the 
advertisements occurring in the New England Journal of Medicine, so we are under the 
assumption that they are the same advertisements.   
While each advertisement appearance was recorded, unique advertisements were 
used as the primary unit of analysis for this study.  A unique advertisement is an 
advertisement that is used multiple times in different magazines at different time periods 
with the same pictures, illustrations, themes, or information.  Unique advertisements are 
fairly important because they may have a different target audience depending on the 
message of the advertisement for that product in that specific magazine or season.  Table 
1 displays the number occurrences of weight-loss advertisements and also the number of 
unique advertisements the industry decided to create.   
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Each advertisement was coded using a content coding tool accounting for all of 
the variation within the advertisement (Appendix 3 and 4).  The over-the-counter weight-
loss product advertisements was coded differently from the prescription weight-loss 
product advertisements due to the regulations regarding the prescription drug advertising.  
Each advertisement was coded for the length of the advertisement, the type of 
advertisement, the length of the directive page(s), and the visual cues within the 
advertisement.  The advertisements were also coded for the race gender and clothing of 
people and the social environment; the directives and contraindications; the claims about 
effectiveness; mechanism for losing weight and the lack of certain side effects; and 
superiority claims (Appendix 5 explains the general criteria for evaluating these 
advertisements).  Appendix 6 is a variable measurement section which displays the way 
the variables from the content coding tool were used throughout the analyses.   
From this information, frequency and correlations of the techniques used in each 
class of products (over-the-counter or prescription) will be used to analyze the 
hypotheses.  More specifically, these two classes of visual and textual cues will be used 
to analyze each advertisement: medical effectiveness and side effects, and identity 
rewards. 
A qualitative analysis of these advertisements will occur using these content 
coding tools.  Given the nature of this dataset, a quantitative study is not feasible.  
Consequently, the conclusions drawn from this dataset will be suggestive rather than 
conclusive.  However, given the lack of work in this area analyzing the content of over-
the-counter and prescription weight-loss advertisements, suggestive evidence will be 
valuable for future research and for better understanding of this area of study. 
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Testing Hypothesis 1 
Using every recorded occurrence of the unique advertisements, the frequency of 
individuals depicted in the advertisements will be analyzed and compared against the 
readership data for each magazine.  In order to test whether the firms were considering 
the concept of high and low involvement, Pearsoncorrelation analyzes will be performed 
comparing the race and gender of the individuals presented within the advertisement 
against the readership of the magazines. 
`Testing Hypothesis 2 
Differences in firms’ advertising behavior will be analyzed by looking at each 
unique advertisement as the firms’ final decision regarding visual cues.  The frequency of 
before and after pictures, social depiction, potential consequences of using the product 
(i.e. amount of weight lost), and clothing of the individuals within these advertisements 
will be analyzed and interpreted based on the theoretical framework regarding how firms 
use the knowledge of the psychology of advertising.  In addition to the visual cues, the 
frequency of each nature of the advertisement appeal will be compared among the three 
markets to discover trends in marketing techniques.  Because the firms chose to use each 
advertisement appeal, every nature of appeal in the advertisement is necessary to analyze.  
The firms’ decision to use every nature of appeal is strategic in nature, so it is important 
to take note of each appeal. 
Testing Hypothesis 3 
The risk information disseminated in prescription advertisements is necessary by 
the FDA, but is not required formally by the FTC in over-the-counter advertisements.  In 
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order to test hypothesis 3, the frequency of directives and side effects in each unique 
advertisement will be analyzed and compared among the three different markets.  In this 
analysis, Side effects were determined by identifying any expected effect not associated 
with any therapeutic benefit.   The directives were classified as any textual cue that told 
the patient to perform some action prior to taking the medication.  An example would be 
“contact your physician,” “Medication must be taken with diet and exercise,” or “See 
your doctor if you are taking cyclosporine”.  A composite score of the occurrence of risk 
information will be divided into directives and potential side effects.   
Testing Hypothesis 4 
The differences in advertising regulations between over-the-counter and 
prescription drugs are fairly large and costly to the firms.  In order to measure the effect 
of these regulations, and specifically the fair-balanced clause within the FDA guidelines, 
the frequency of risks and benefits in each advertisement will be analyzed.  Risks were 
classified as any side effect or adverse event associated with taking the product.  Some 
directives were also included as a risk because of the possible detrimental effects to the 
body.  Benefits were classified as any claims of losing weight, boosting energy, and 
losing inches on a certain part of the body.  Other claims included were positive clinical 
information data and claims of raising self esteem.  The data collected was used to create 
a composite score for each advertisement, which was analyzed and compared among the 
direct-to-consumer prescription and over the counter advertisements and the physician 
directed advertisements.  In order to maintain consistency across all markets, the 
directives page for the prescription drugs was not analyzed because the over-the-counter 
products are not required to disseminate this information.   
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Testing Hypothesis 5 
Due to the withdrawal of some weight-loss products because of safety 
considerations, we will analyze the unique advertisements for the use of safety claims 
within their advertisements.  Claims like “no increased incidence of valvular heart 
syndrome”, “unlike anything that came before”, “unlike any other weight-loss 
medication”, “does not contain PPA or ephedra”, “fen-phen results without the side 
effects,” or “safe” will be used to assess whether the pharmaceutical companies are trying 
to advertise the benefits of their products compared to recently withdrawn products.  This 
is useful in product differentiation and the ability to improve the image of the product 
through claims of safety.  Consequently, any safety claim found within the advertisement 
has been noted and will be analyzed in each respective market.   
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8. Results 
Descriptive results 
The database of 65 unique over-the-counter, 11 prescription direct to consumer, 
and 16 prescription direct to physician print advertisements contains elaborate 
information about the firms’ advertising decisions given the economic constraints they 
face.  Figure 1 and 2 represents the firms’ decision to advertise in certain magazines and 
the frequency an advertisement was found in that particular magazine.  Table 2 describes 
the average readership of the magazines that firms decided to place advertisements.  The 
average readers of these magazines tend to be white women, between the ages of 25-65.  
Readership information is displayed in Table 2.   The occurrence of 
advertisements within each magazine differs based on its classification as over-the-
counter or prescription products.  For over-the-counter products, the magazine readership 
is on average more female than that of the magazine readership in which prescription 
DTC advertisements were identified.  Furthermore, the concentration of advertisements 
differs drastically as seen in Table 2 and Figure 1 and 2.  The majority of the over-the-
counter advertisement appearances occurred in two magazines Glamour and Women’s 
Day (See figure 1 and 2).  The prescription DTC advertisements appeared in more 
magazines and at lower frequencies.  The two magazines with the most prescription DTC 
advertisements (People and US News) accounted for 28 percent of the advertisements 
compared to 86.91 percent of the advertisements found in Glamour and Women’s Day.  
The over-the-counter products are concentrated in fairly female oriented magazines, 
whereas the prescription products are evenly distributed across a wide range of 
magazines. 
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Upon further analysis of the over-the-counter market, firms shifted the magazines 
in which they chose to place advertisements between 1994 and 1995.  Figure 5 shows the 
magazines with the most over-the-counter weight-loss advertisements between 1985 and 
2002.  Based on this histogram, there appears to be a shift in firms’ advertising 
preference in magazines.  In 1995, there appears to be a change in the number of 
advertisements presented in Cosmopolitan and Glamour.  Glamour assumes the role of 
the largest supplier of weight-loss advertisements to the consumer after 1995.  In the 
broadest sense Cosmopolitan and Glamour can be seen as substitutes, due to their similar 
readership and content (See Table 6).  Although variation does occur between years, the 
general readership of the magazines generally remains constant in the long-run.  The only 
variation in the readership data is the gender data.  In 1995, females consisted of only 
66% of the readership for Cosmopolitan and 74% for Glamour.  While the female 
readership for both these magazines increased over the next few years, this slightly larger 
readership may explain the switch.  Unfortunately, readership data before 1995 is 
unavailable. 
The shift in firms’ decision to use Glamour after 1994 is also accompanied by a 
substantial decrease in the length of the advertisements.  Figures 13a and 13b describe the 
nature of this shift.  The firms who presented their advertisements in Cosmopolitan used 
at least one page advertisements 87.07 percent of the time, while the firms who 
advertised in Glamour with used at least one page advertisements 26.67 percent of the 
time.  With shorter advertisements, firms save money while also reducing the amount of 
information revealed to the consumer.   
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Given the constraints on the over-the-counter firms, the DTC over-the-counter 
advertisements were shorter with 41 of the 65 unique advertisements under 1 page with 
an average size of 12.92 in2 (Table 4).  Twenty-four of the unique advertisements were 1 
page and none were longer than one page.  There were no directive pages, but there was a 
wide range of product types being advertised, ranging from bars and shakes to creams 
that claim to reduce cellulite.   
The economic constraints on prescription firms differ from over-the-counter 
firms.  The advertisements for prescription weight-loss products are longer with most 
advertisements being 2 to 3 pages not including the directive pages (Table 4).  While 
these advertisements are longer, they tend to use on average less visual stimuli.  All of the 
prescription advertisements used text to make their claims.   
Hypothesis 1 Results  
H1: Firms will choose to place advertisements in magazines targeted toward 
female readership magazines and thus will portray women more frequently than 
men.  In addition to the gender differences in the target audience, firms will also 
advertise in magazines with higher white female readerships and will portray 
more white women than African American or Hispanic women.   
 
Pearson correlations reveal that within the over-the-counter DTC advertisements 
the occurrence of white individuals was positively correlated with white readership (ρ= 
0.26464, p = 0.0150).  This positive relationship explains that firms’ decisions to create 
advertisements with the presence of white individuals varies (in the same direction) with 
the placement of those advertisements in magazines with white readership.  Correlations 
with readership data of other races (Table 2) show statistically significant negative 
relationships (p < 0.05) with the occurrence of white individuals found within the 
advertisement with the exception of Asian readerships (ρ= -0.13807, p = 0.2104).  This 
relationship is the opposite of the usage of white individuals in magazines with white 
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readerships.  The presence of a negative correlation occurring in the presence of white 
individuals in these advertisements and the placement in magazines with readerships 
higher in other ethnicities displays the selective nature of the advertising of weight-loss 
products.   
The correlations for prescription DTC advertisements were similar but were seen 
with a higher confidence level.  The relationship between the presentation of white 
individuals within the advertisement and the percentage of the readers being white was 
ρ= 0.51364, (p <0.0001).  The higher confidence level and the larger value of rho indicate 
that the firms’ decisions to place white individuals in advertisements vary (in the same 
direction) with the percentage of white readers of that particular magazine.  The 
presentation of a white individual within the advertisement was negatively correlated 
with readership data of other races with a significance level of p <0.015 (Table 2).   
The relationship between the appearance of males and females within the 
advertisements and readership of the magazines displays the firm’s ability to advertise to 
a specific audience.  Pearson correlation results show a positive ρ for the appearance of 
females within the over-the-counter advertisements and a female readership within the 
magazines (ρ = 0.23659, p=0.0303).  The appearance of a male individual within an over-
the-counter advertisement is negatively correlated with a male readership (ρ =-0.20106, 
p=0.0667).  The prescription DTC advertisements show a similar relationship with the 
correlation of ρ=0.30763 (p=0.0073) for the appearance of a female in an advertisement 
and the magazine having a predominantly large female readership.  The correlation for 
the appearance of a male in an advertisement and a male readership was ρ=0.30763 
(p=0.0073).  
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While these correlation coefficients are significant to a p < 0.05, the coefficients 
were not large enough to make any significant conclusions.  These results simply reveal 
that the relationships were as predicted, but the values of rho were not nearly as large to 
establish causality or a trend.   
Hypothesis 2 Results 
 
H2: Prescription advertisements will include fewer images of individuals and will 
use more information when compared to the over-the-counter products due to the 
differing advertising regulations.  
 
The presentation of individuals within advertisements is extremely important and 
plays a large role in the transformative power of the advertisement.  Bandura (2001) and 
Roth (2003) both exhibit the importance of social cues within advertisements.  Table 5 
displays the frequency of how individuals were portrayed within each advertisement.  
There are systematic differences between the advertisements’ presentation of individuals.  
For example, the use of individuals wearing bathing suits in over-the-counter 
advertisements was 0.4154 per advertisements or occurred 27 times whereas the firms of 
prescription products chose not to use any individuals wearing bathing suits.  The 
absence of the use of bathing suit in prescription advertisements displays a lack of use of 
exhibiting the “desired end state” of the product which can be attributed to the “fair-
balance act” within the FDA regulations.  While the use of bathing suits provides images 
of “desired end states,” the use of athletic clothes provides images of motivation.  Within 
the physician advertisement, the frequency of individuals wearing athletic clothes was 
approximately equal to that of the over-the-counter advertisements.  This begins to reveal 
the messages that these prescription advertisements are trying to convey, which is that 
there must also be lifestyle changes in order for the product to be fully effective.   
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The occurrence of individuals in general was more prevalent in the over-the-
counter and the direct to physician prescription advertisements.  In terms of social 
depiction and demeanor, most individuals were depicted as happy or smiling within the 
advertisement.  Less than half the time were they shown with no particular expression on 
their face and rarely were they ever shown as sad or stern (Table 5).  The use of happy 
and smiling people shows the potential transformational effects of the product.  
Essentially through using happy and smiling people, the advertisement tells the consumer 
that they will be happier if they take this product.  The use of the social depiction 
revealed over-the-counter and prescription direct to physician advertisements were more 
likely to depict individuals alone where as the prescription DTC advertisements were 
more likely to show individuals with other people.   
The overall nature of appeal showed very little variation between the three classes 
of advertisements.  Because each advertisement could potentially have more than one 
advertisement appeal, the following data represents the aggregate data regarding nature of 
advertisement appeal.  For both direct to consumer and physician, 81.1 percent used a 
nature of appeal of informative/statistics & studies to inform the consumer or physician 
of their product.  However, the over-the-counter firms used informative/statistics & 
studies to persuade the consumer 57.8 percent of the time.  The firms of prescription 
weight-loss products used primarily safety, health, and nutrition and informative, 
statistics, and studies as their dominant advertisement appeals.  The firms of the over-the-
counter weight-loss products used a greater variety of nature of advertisement appeals as 
seen in Figure 6.  
Hypothesis 3 Results 
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Advertisements directed toward physicians will contain more clinical trial data 
than the consumer directed advertisements.  Furthermore with regards to the 
dissemination of risks, physician advertisements will contain more risks within 
the body of the advertisement than the consumer advertisements.   
 
The use of effectiveness information in the form of clinical and anecdotal studies 
is a valuable tool for these firms.  Figure 7 shows the frequency of which these firms use 
clinical and anecdotal studies to convey effectiveness information.  Physician-direct 
advertisements of prescription weight-loss products in this sample used mainly clinical 
study data to show its effectiveness.  Although these firms did use anecdotal studies to 
promote their product to physicians, the use of anecdotal data was a method used by 
firms selling over-the-counter weight-loss products.  Ironically, the firms did not use 
these clinical studies to promote their product to consumers.   
Figure 8 more specifically reveals the number of claims of effectiveness 
information disseminated within the advertisement.   On average the prescription direct to 
physician advertisements presented 2.375 clinical study claims per advertisement.  With 
regard to these claims, all of them cited that over 50% of the patients had at least a 5% 
weight-loss reduction in one year.  The claims for mean weight-loss varied from 13.4 to 
26 lbs in one year.   
The use of anecdotal data within prescription direct to physician advertisements 
was found in two of the sixteen unique advertisements.  Within these two advertisements, 
one cited a blood pressure drop from 160/80, which is considered hypertensive to 110/80 
as well as a weight loss of 46 lbs.  The other advertisement cited anecdotal evidence of an 
individual who lost 27 lbs.  
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The frequency of drug mechanism claims directed at both over-the-counter and 
prescription consumers are relatively the equal (Figure 9).  However, the frequency of 
these claims is considerably higher for advertisements directed at physicians.   
Risk information is very important when assessing the efficacy of a drug.  Figure 
10 displays the frequency of risk information per advertisement.  On average the 
prescription products have more directives and side effects claims than the over-the-
counter products.  However within the prescription products, the consumer 
advertisements have more directive and side effect claims than the physician 
advertisements.  Within consumer advertisements for prescription products, there is little 
variation regarding the frequency of risk information within the advertisements.  The 
physician directed advertisements display more variation regarding the amount of 
disseminated risk information. 
Hypothesis 4 Results 
H4: Based on the difference in regulations between prescription and over-the-
counter drugs, advertisements for over-the-counter drugs will present more 
benefit information and less risk information than DTC advertisements of 
prescription drugs.  
 
While the presentation of risk information is extremely important, the amount of 
benefit information disseminated is important to display the effectiveness of the weight-
loss products.  Figure 11 shows the occurrence of the risks and benefits per 
advertisements.  The use of risk information is significantly greater for the prescription 
advertisements.  Conversely, the claims of benefits per advertisement is 2.65 and 2.15 for 
physician directed advertisements and over-the-counter consumer advertisements 
respectively.  The dissemination of benefit claims occurs 1.167 times per advertisement.  
From these frequencies the benefit risk ratio was determine.  While the benefit/risk ratio 
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remains below 1 for prescription products, this ratio is 8.67 for the over-the-counter 
advertisements.   
Hypothesis 5 Results 
H5: After the withdrawal of weight-loss products the pharmaceutical companies 
will try to advertise the benefits of their remaining over-the-counter products in 
comparison to those that were withdrawn from the market due to adverse side 
effects (or subjects to FDA warnings).   
 
The number of safety claims and product differentiation claims are very important 
within this market given the potential for adverse events (Figure1).  The withdrawal of 
Pondimin, Redux, and PPA brought a lot of attention to the weight-loss market.  The use 
of safety claims reassures the patient that these products can factor due to the number of 
products that were recalled within this therapeutic class.  The over-the-counter 
advertisements use 0.538 times per advertisements compared to the 0.1875 times per 
advertisement that are seen in prescription physician directed advertisements.  There were 
no safety claims within the prescription DTC advertisements.   
Although the safety claims provide a sense of reassurance, the presence of 
product differentiation has become an effective tool for advertising.  In fact, the 
prescription DTC advertisements use this technique five times or 0.455 per 
advertisement.  Claims include “And it’s unlike anything that came before” or “Unlike all 
other prescription weight-loss medications, which work on the central nervous system…”  
The prescription physician advertisements claim lower or no incidence of pulmonary 
hypertension or heart valve issues.  The frequency of this type of claims occurred in three 
out of the 16 unique advertisements or 0.188 times per advertisements.  Within over-the-
counter advertisements, claims of the product having non-addictive chemicals or 
stimulants or containing chemicals other than PPA and Ephedra were seen as product 
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differentiation claims.  The frequency per advertisement for over-the-counter products 
was 0.138, which means this technique was used in nine of the 65 unique advertisements. 
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9. Discussion 
Firms act rationally to maximize their profits through maximizing the sales of 
their weight-loss products.  In their advertising of weight-loss products, these firms are 
constrained by the way consumers react and the advertising regulations set by the FDA 
and the FTC.  The purpose of this research was to assess the mechanisms used by firms to 
increase consumers’ awareness of their product.  Essentially when deciding to advertise, 
firms must decide the target audience and the visual and textual cues prior to placing an 
advertisement in a magazine.   
Magazine placement has shown to be critical in efficiently targeting a specific 
audience.  The target audience of these advertisements and the occurrence of these 
advertisements reveal a lot about the market for weight-loss products and firm behavior.  
The concentration of over-the-counter advertisement in Glamour and Women’s Day, two 
magazines with predominantly female readership, further supports the idea that women 
are more concerned with their weight.  Given the market for over-the-counter weight-loss 
products, these firms appear to be targeting female audiences because of their increased 
propensity to use weight-loss products.  According Blanck et al. (2001), females are 4.9 
times more likely to use weight-loss products than males.  While the firms of over-the-
counter advertising chose a select niche of magazines to advertise in, the prescription 
direct to consumer firms for weight-loss advertising appears to have a broader focus in 
terms of advertising to a specific group.  These firms chose People and US News and 
World Report to advertise strongly in, which has a much larger male readership 
compared to the Glamour and Woman’s Day.  This trend toward advertising to a broader 
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audience follows the general market for prescription weight-loss products as discussed by 
Cawley and Rizzo (2005) and Blanck et al. (2004). 
Although, this trend is not fully supported through the testing of hypothesis one, 
the direction of the relationships were as expected, but the strength of the correlation was 
not high enough to establish any trends.  The correlations of pictures of individuals 
within the advertisements and the race of the readership population begin to show the 
relationship between the appeal of the advertisement and the target audience of the 
advertisements.  The over-the-counter advertisements were fairly skewed in their 
presentation of individuals.  In fact, of the 84 appearances of over-the-counter 
advertisements, 47 females and 9 males were shown.  Of these individuals, 50 were white 
(6 could not be identified due to the quality of the scanned advertisement on file).  The 
lack of variation introduces an inability to determine whether these advertisements would 
change if they were to be placed in other magazines.  Furthermore, the absence of 
advertisement in selected magazines, like Jet and Ebony reveal the firms’ decision to 
advertise to certain population.  Given the evidence of the individuals within the 
advertisement, the target audience for these over-the-counter products is primarily white 
female women.   
Similar to the OTC correlation results, the correlation for prescription DTC 
advertisements between the presentation of white individuals within the advertisement 
and the readership being white was not as high enough to have confidence for any 
conclusions to be made about firms’ decisions.  The firms’ decisions to use images of 
people were very selective and were limited usually to female patients.  This is mainly 
due to relatively few prescription advertisements that chose to use images of people.  
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Furthermore, a few advertisements for Xenical used infants within their advertisements 
who in some ways play a role in eliciting a response from females.  The other reason is 
that in the one unique advertisement that appeared three times, a female patient was 
presented with a male physician.  Consequently to say that this individual is part of a 
marketing technique that is aimed at male readers is hard to believe.  In fact this 
advertisement is aimed largely at females because in addition to the image of the 
interaction between the female patient and the male physician, there is an image of a baby 
with the tagline, “In the beginning, your weight was in the capable hands of your doctor.  
It still should be.”  The target audience of this advertisement is middle-aged women, but 
the theme is to ask your physician about this prescription product. 
Overall, there was a trend of firms attempting to target a population, but there 
appears to be a visual or textual cue exogenous of the individuals within the 
advertisements.  While these correlations results reveal general trends, the firms appear to 
be selectively choosing their magazines according to readerships.  An analysis of the 
occurrence of advertisements in select magazines between 1985 and 2002 revealed the 
shift between 1994 and 1995 from Cosmopolitan to Glamour that is not fully explained 
by a change in target audience.  In 1994, the Dietary Supplement Health and Education 
Act moved the burden of proving the safety of the dietary supplements to the firm rather 
than the FDA (P.L. 103-417 §8)3.  The effect of this change has caused an increase in the 
number of dietary supplements claiming weight-loss effects and about a 10-20% annual 
increase in the number of products marketed as a weight-loss product between 1997 and 
2001 (Cleland et al., 2002).   
                                                 
3 P.L. 103-417 §8 – Dietary Supplement Health and Education Act of 1994 
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Coinciding this shift in magazine placement, the advertisements also became 
shorter after 1994.  According to Cleland et al. (2002), the number of actions taken by the 
FTC for deceptive advertising increased from nine in the 1980s to 81 in the 1990s.  This 
increase begins to explain the FTC regulatory power in its ability to alter firm advertising 
behavior and may also explain the rise in advertisement under one page.  The use of 
advertisements less than one page may be a reaction to the FTC’s action against the 
industry.  With a shorter advertisement, the amount of information disseminated 
decreases along with the claims, which may begin to reduce the false or misleading 
claims.  Unfortunately, this does not fully explain the shortening of the advertisements 
because the absence of pertinent product information can also be considered false or 
misleading.  Consequently, the firms’ decisions to shorten advertisements are not fully 
explained by the market conditions.   
The differences in the regulations of advertising have led to prescription product 
advertisements to be significantly longer.  As discussed previously, the dissemination of 
all risks indirectly requires that all advertisements be at least two pages, one page for the 
actual advertisement and then a second page of fine print disclosing all the risks (Table 
3).  The FDA regulations establish rules, which attempt to protect consumers from false 
and misleading advertising, but at the same time increase the firms’ advertising costs.  
This appears to result in little variation among the prescription advertisements.  For 
example, of the three Meridia DTC advertisements, all three show slightly different 
images of plates half full, but the main text of the advertisement is essentially the same 
for each advertisement, despite changes in the images of the products.  Similarly, five 
unique advertisements for Xenical are virtually identical with the exception of the 
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number of pages of the advertisement and some minor changes which includes “Do not 
take if you are taking cyclosporine” to “See your physician if you are taking 
cyclosporine.”  The regulatory environment surrounding prescriptions products limits the 
number of unique advertisements in this market, which can be seen by the minor 
alterations of these advertisements.  The costs for firms to create new unique 
advertisements are relatively large given the need to comply with all of the FDA 
regulations for print advertising.   
The systematic differences in length of advertisements, not only affect the costs to 
the firm, but also reveal the amount of information presented to the consumer.  Table 3 
displays the use of textual and visual cues across the three classes of advertisements, but 
this reveals little about the advertising mechanisms revealed.  Hypothesis 2 and 3 assess 
to see whether these regulations have an affect on whether or not these regulations have 
an effect on the information disseminated to the consumer.  Hypothesis 2 was supported 
due to the absence of bathing suits in the prescription advertisements.  Clothing on an 
individual in these advertisements has the ability to show the potential effectiveness of 
the product by showing “desired end states”(Roth, 2003; Welch Cline & Young, 2004).  
The use of bathing suits and/or athletic and workout clothes shows the transformative 
power of the product, meaning this product has the ability to make me look like her.  
While the use of athletic clothes displays that the consumer will be motivated or have the 
energy to be like her if this product were taken.  The use of transformative messages 
appear follow the course of the peripheral route according to Petty and Cacioppo (1983) 
which in their analysis appeared to be more effective in eliciting a response from 
individuals.  It is hard to determine whether this is an effect of the regulations or a 
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voluntary choice by the prescription firms, but the use of bathing suits appears to be an 
important aspect to consider when assessing these advertisements.   
Social depiction as well as the demeanor of the individual is also extremely 
important.  Social depiction is very powerful in its ability to improve brand awareness 
through transformative cues (M.S. Roth 2003).  The use of social cues and social 
depiction is further supported in research from Schooler et al. (1996) regarding the use of 
social depiction on billboard advertisements for alcohol and smoking products.  
According to Bandura’s (2001) theory of observational learning, the potential for social 
depiction to elicit a response by a consumer to either purchase a product or to ask their 
physician makes the social depiction within an advertisement very important.  If the 
advertisement happens to make a connection with an individual by providing an image of 
her “desired end state” and if the consumer can identify with the advertisement or the 
individuals within the advertisement, the effectiveness of the increases substantially as 
the probably the consumer will move to acting on the advertisement increases.  Because 
of this evidence, it is also not surprising to find that not one person within the 
advertisements were seen as sad/stern (only examining the after image of a before and 
after image).  The only occurrence of a sad/stern face was in the before image of a before 
and after picture.   This example classically shows the firms decisions to promote the 
transformative power of their product.   
All of the claims within these advertisements result in an overall nature of ad 
appeal.  The presence of these appeals provides an excellent summary of the 
advertisement claims and the manner in which the firms are attempting to elicit a 
response.  Prescription advertisements tended to use the “safety, health, and nutrition” 
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and the “informative, statistics, and studies nature of ad appeals” because of the 
constraints imposed by the FDA regulations.  Overall, the prescription firms are limited 
by the FDA regulations.  Conversely, the freedom that over-the-counter products face 
reveals the possible potential for improving profits.  The ability to use sex appeal and 
celebrity appeal are two major themes that have the potential to drastically change the 
over-the-counter market.  As noted previously, Priester and Petty (2003) found that the 
use of a spokesman has the potential to improve brand awareness as well as increase 
retention of information.  Though some other classes of prescription products have begun 
to use spokesmen, like athletes and celebrities, the weight-loss product market has rarely 
used these marketing strategies.   
The use of transformative cues has been shown to be the most effective in 
improving consumer awareness, but the regulations require some textual cues regarding 
effectiveness and risks claims.  In fact, the use of effectiveness information is especially 
important in maximizing profits.  Although the presentation of this information may not 
be conducive or effective within advertising, firms are required to include this 
information and consequently attempt to differentiate their product through their 
effectiveness claims.  Clinical study information is the most effective way prescription 
products show their effectiveness, yet due to the medical information that must be known 
to interpret these results, only the firms advertising to physicians choose to use this 
information.  Within physician-directed advertisements, the use of clinical studies as a 
source of evidence occurred on average 2.375 times (Figure 8).  The prevalence of this 
type of information aligns with Petty and Cacioppo’s theory of high involvement and 
central processes.  An individual more specifically a physician will be more likely to 
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understand and rationally consider this information than a normal consumer because the 
physician has been trained to understand this type of information.  In order to maximize 
the effectiveness of the dissemination of clinical study information, firms respond by 
targeting those populations who are highly involved and aware of the potential benefits, 
in this case physicians.  While advertisements are not the only source of information for 
physicians, advertisements can improve product and manufacturer recognition.   
The anecdotal evidence used within over-the-counter weight-loss products is 
sometimes the only information that the consumer receives.  Compared to clinical study 
evidence, anecdotal data requires low involvement to understand and use for decision 
making.  The use of this type of information targeted toward the less informed consumer 
(compared to physicians on average) is supported by Petty and Cacioppo (1981) in their 
description of the peripheral processes.  The use of the type of information will attract 
individuals who are not willing to weigh the true costs and benefits of the product, but 
will base their decision on other factors like the individuals or the anecdotal data in the 
advertisement. 
While the use of effectiveness information is largely important for a firm’s 
decision, the use of mechanism information is prevalent in all three markets.  Figure 9 
show the variation between physician-directed advertising and direct-to-consumer 
advertising.  The use of mechanism images to depict the location of action was seen in 
76.7% of the physician-directed advertisements.  For Meridia, this usually included 
images of neurotransmitters and the way sibutramine blocks the reuptake of 
norepinephrine and serotonin or an image of the brain pointing to the location of the 
appetite control center.  For Xenical, the mechanism images were of triglyceride 
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molecules with the drug Orlistat binding to these molecules and preventing them from 
being absorbed in the intestines.  The presentation of these images within the physician 
advertisements displays the firms’ use of different marketing strategies based on aspects 
other than race and gender, in this case education level.   
The presentation of risk information in these advertisements is very important in 
warning both the consumer and physician of the potential hazards of using the product.  
Due to regulation differences, there is a large difference between the dissemination of 
risk information for over-the-counter and prescription weight-loss products.  According 
to the FTC, as long as the advertisement presents truthful information in a non-deceptive 
or misleading way then it complies with their regulation.  However, any omitted 
information that results in a misleading claim is seen in violation of the FTC regulations.  
Based on this information, these regulations allow for more freedom in the presentation 
of information, specifically risk information, which can be seen in Figure 10.   
Prescription advertising faces a much different regulatory authority.  The FDA 
regulations state that all risks within the drugs label must be presented in a manner that 
displays “fair-balance.”  The difference in the presentation of risk information between 
the consumer directed and the physician directed advertisements lies mainly in the 
number of directives that must be disclosed to the consumer.  These include major 
contraindications, “use in conjunction with diet and exercise,” “tell your doctor if you 
have ____ condition,” “this product is not intended for everyone,” and “see your doctor 
for more information about this product.”  These directives increase the cost of 
advertising by essentially requiring the length of the advertisement to be longer to 
accommodate these directives.  While the direct-to-consumer advertisements use these 
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directives to ensure proper usage of the products, the direct-to-physician advertisement 
acknowledge that the physicians are the providers of care for the consumers and 
essentially act as a gatekeeper – determining appropriate use for the product.  
Consequently, fewer, but more specified and technical directive information is provided 
to physicians.   
While the number of directives presented in the consumer advertisements is 
substantially larger, the variation in the number of side effects is larger for physician 
advertisements.  Upon further analysis of these advertisements, the use of clinical data 
was used to present the occurrence of side effects.  While the dissemination of these side 
effects is considered risk information, the manner in which they were presented makes 
them more of a benefit.  Using the comparison to the placebo trials, the firms were able to 
use the requirement of the stating the risks of the product label to promote some of the 
benefits of their product, in this case the low occurrence of side effects.  Consequently, 
much of the risk information presented within physician advertising could be considered 
benefit information because they were claiming a low-incidence of side effects. 
The dissemination of side effects is essential to maintain a market that depends on 
information.  While this information may reduce the effectiveness of the advertisements, 
the firms are required to provide this information under the “fair-balanced” clause of the 
FDA guidelines.  The frequency table shows that the risk information is nearly double the 
frequency of benefit information per advertisement for prescription products (Figure 11).  
Given the FDA regulatory policy, and the relative nature of these products, these firms 
may have more room to advertise the benefits of their product, given the fact that their 
benefit-risk ratio is well below 1.  In fact, the prescription DTC advertisements only 
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claim that the product will help you lose weight and keep weight off.  In all 11 unique 
advertisements, neither of the firms chose to advertise their clinical studies.  Yet due to 
the nature of this market and the recent withdrawals of Redux and Pondimin, these two 
firms may be waiting for more phase IV clinical trials to improve their claims and more 
efficiently promote their product. 
With the withdrawals of Redux and Pondimin from the prescription market and 
PPA from the over-the-counter market, the overall market for weight-loss products has 
seen a dramatic decrease in sales and prescriptions written.  In addition to these 
withdrawals, the warnings about ephedra further exacerbate the market conditions for 
weight-loss products.  As a result of these withdrawals and warnings, some firms have 
responded by providing safety claims and/or product differentiation claims.  With respect 
to prescription DTC advertisements, the firms appeared to have responded to these 
market conditions by differentiating their product from the withdrawn products.   
Consequently, Xenical used the statement “Unlike all other prescription weight-loss 
medications, which work on the central nervous system…” and Meridia stated “And it’s 
unlike anything that came before.”  Within physician directed advertisements, the lack of 
clinical diseases like pulmonary hypertenstion or heart valve disease associated with 
Redux and Pondimin were cited as evidence for increased safety and for product 
differentiation.  Meridia also claims (within its physician directed advertisements) that it 
is well-tolerated by 4600 patients in 1998 and 1 million patients in 1999.  Firms attempt 
to separate their product from the withdrawn product to recoup the market share lost 
during the recalls in 1997.   
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The over-the-counter firms mainly use: claims of non-addictive, contains no 
stimulant, or does not disrupt metabolism to present an image of a safe product.  While 
these safety claims are evident in this market (Figure 12), the use of product 
differentiation claims is not absent.  The inclusion of ingredient names is the major way 
these products attempt to differentiate from ephedra and PPA.  Consequently, firms claim 
their products have the GAFA complex, Chromium Picolinate, Pyruvate, or L-Camatine 
in order to show that their products are different from PPA and ephedra.   
The withdrawal of Redux, Pondimin and PPA has severely damaged the market 
for weight-loss products.  The use of product differentiation is a means to regain the 
market share lost due to these withdrawals.    
The rise in obesity poses a large problem for the United States.  With most 
attempts to lose weight failing, the need to find an effective therapy is becoming 
necessary to curb the costs of obesity and its co-morbid conditions.  The use of weight-
loss products provides a potential solution to this growing problem.  This analysis of the 
marketing techniques for weight-loss products sheds some light into the ways these firms 
choose to increase their sales.  The potential benefit of these products to reduce the 
prevalence of obesity exists to an extent, but some of these products have debilitating and 
fatal effects, yet individuals still chose to take these products.  The potential risks 
associated with these products are important to consider when analyzing these 
advertisements.   
The information taken from this research reveals vital information to the way 
firms respond to the market.  From this information, it is clear that firms of prescription 
products are at a severe disadvantage when compared to firms producing OTC 
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advertisements.  The techniques that Roth (2003) explained to increase consumer 
responsiveness are absent in this class of drugs.  Furthermore, the use of visual and 
textual cues that elicit peripheral route cognitive processes (Petty et al., 1983) are absent 
in the prescription market.  Furthermore, Roth (2003) also found that disease, symptom, 
and risk information was ineffective in recall, though the main mechanisms used in the 
advertising of prescription weight loss products was predominantly, risk and side effect 
information.   
As we compare these OTC and prescription market, we see that the OTC market 
is not constrained as heavily by the FTC regulations.  The lack of specificity in the FTC 
regulation allows for a broader interpretation and thus allows for a larger variety of 
advertisements.  The firms’ use of more attractive individuals and anecdotal information 
display their rational decision to show “desired end” states, which plays a significant role 
in influencing consumers.  While the OTC products are not required to disclose all the 
risks and side effects, they do have the responsibility to include some statement regarding 
the potential risks because a failing to disclose vital information can be considered a form 
of deceptive advertising.  Future research should begin to look at the advertising behavior 
of firms whose products have gone from prescription to OTC to analyze the difference in 
claims based on regulation.  With Xenical now available in the OTC form, research in 
this specific market may be feasible within the next few years.   
This research begins to reveal the main messages these firms are attempting to 
convey to the consumer.  Unfortunately, due to the qualitative nature of this research, all 
conclusions are suggestive, though this research introduces the marketing methods used 
by these firms to persuade consumers to purchase their product.  Given the safety of these 
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products, there is a need to consider the potential implications of using these products.  
The growth of advertising has increased the amount of information available to 
consumers, which has both positive and negative effects.  Calfee (2002) states that DTC 
advertising has improved the consumers’ awareness of products related to their diseases, 
which has placed the burden of the decision on the physician.  Furthermore, the growth of 
the OTC market has removed the physician from some of the decision process as 
individuals may move from prescription products to over-the-counter products.   
With the rise in prevalence of obesity, the potential for individuals to begin 
pursuing these products rises.  With the risks associated with some of the products, the 
potential for adverse events rises as individuals are attracted to the OTC products that do 
not require physician supervision.  As this market continues to grow, especially with 
products like Xenical moving into the OTC market, the advertising of weight-loss 
products may begin to serve as a benefit if the physician is included as a safety 
mechanism to reduce the potential risks of these products.   
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Table 1. Occurrence of Advertisements within SCADS Archive 
 
 
OTC DTC Prescription 
DTC 
Prescription 
DTP
Advertisement Appearances 
(1985-2003) 392 84 95
Advertisement Appearances 
(1997-2003) 75 84 95
Unique Advertisement  
(1985-2003) 177 11 16
Unique Advertisements  
(1997-2003) 65 11 16
 
Table 2. Overall Readership Data for Direct to Consumer Advertising of Weight-Loss 
Products 
  Over-the-Counter DTC Prescription DTC 
Female  81.81% 65.35% Gender 
Male 18.19% 34.65% 
Asian 2.44% 2.96% 
Black  11.62% 10.44% 
Hispanic  11.29% 10.20% 
Other 3.93% 3.62% 
Race 
White 73.16% 75.73% 
18-24 18.15% 11.44% 
25-39 35.85% 29.52% 
40-64 35.30% 42.27% 
Age 
65+ 10.70% 16.76% 
Less than HS 13.35% 12.38% 
HS Graduate 33.17% 32.70% 
Some College 31.31% 28.73% Education 
College Graduate 
or higher 22.18% 26.19% 
 
Table 2 was developed using the average readership of a magazine in which a weight-loss 
advertisement was placed in.  The average number of readers that fell into each 
readership characteristic was found and divided by the average number of readers across 
all magazines to find the percentage. 
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Table 3. Characteristics of Advertisements by class of weight loss product and target 
audience 
 OTC DTC
Prescription 
DTC 
Prescription 
DTC
Advertisement Lengths  
(Frequency)  
 >1 Page 41 0 0
  Width (average (in)) 3.80 0 0
  Length (average (in)) 3.41 0 0
 1 page 24 4 5
 2 page 0 6 2
 3 Page 0 1 7
 4 Page 0 0 0
 > 4 Pages 0 0 2
Directive Page Lengths 
(Frequency)    
 1 Page 0 10 16
 2 Page 0 0 0
 3 Page 0 1 0
Product Types  
(Occurrence per advertisement)    
 PRODUCT NOT SPECIFIED 0.21 0.00 0.00
 CAPSULE 0.22 1.00 1.00
 TABLET 0.02 0.00 0.00
 CREAM 0.06 0.00 0.00
 SHAKE 0.14 0.00 0.00
 BAR 0.08 0.00 0.00
 CAPLET 0.10 0.00 0.00
 PILL UNSPECIFIED 0.37 0.00 0.00
Ad Visuals 
(Occurrence per advertisement)    
 PICTURE 0.81 0.73 0.81
 PRODUCT 0.90 0.73 0.44
 TEXT 0.94 1 1
 CHART 0.04 0 0.31
 TESTIMONIAL 0.05 0 0.13
 CUTOUT 0.04 0 0
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Table 3. (Continued) 
Individuals with the 
Advertisements   
# Before and After Images 
(Number of Occurrences)   
Gender   
 Male 7 0 0
 Female 4 0 0
Race  
 White 11 0 0
 Cannot be identified 0 0 0
Age  
 Adult 11 0 0
   
# Other individuals (Not before and after 
images) 
(Number of occurrences)   
Gender   
 Male 5 1 6
 Female 36 1 7
 Cannot be identified 1 2 0
Race  
 White 35 2 12
 Black 0 0 1
 Cannot be identified 7 0 0
Age   
 Adult 42 2 13
 Infant/Child 1 2 0
 Cannot be identified 1  0
Demeanor  
 Sad/Stern  
 No Particular 
Expression 4 1
 Happy/Smiling  12
Clothing  
 Athletic/Workout 0 1
 Bathing Suit 0 0
 Casual 2 11
 Dress Up 0 1
Social Depiction  
 Alone 2 10
 With Other People 2 3
* Note: All frequencies are taken from the unique advertisements because we are measuring the firms’ 
overall decisions.  Their decisions to place each advertisement in a particular magazine is measured in 
hypothesis 1 and any analysis pertaining to readership data. 
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 Table 4.Correlation of Readership by Individuals depicted within Advertisements 
 
 White Black Asian Other Hispanic 
Over-the-Counter (White 
Individuals Presented within 
Advertisements) 
0.264 
0.015 
-0.313 
0.004 
-0.139 
0.210 
-0.242 
0.027 
-0.183 
0.095 
Prescription DTC (White 
Individuals Presented within 
Advertisements) 
0.514 
<0.0001 
-0.45690 
<0.0001 
-0.445 
<0.0001 
-0.47701 
<0.0001 
-0.281 
<0.0145 
Note: The table above represents Pearson correlation statistics where rho is the top value 
and the p-value is indicated as the lower value.  Correlations were conducted for only 
white individuals presented within advertisements because only white individuals were 
found in these advertisements.  Only in the direct to physician advertising were 
individuals of races other than Caucasian used.   
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Table 5.  Individual Attributes (Average Frequency per Advertisement) 
 
Over the Counter 
DTC Prescription DTC Prescription DTP 
Sad/Stern 0.00 0.00 0.000
No Particular Expression 0.277 0.364 0.063
Happy/Smiling 0.539 0.000 0.063
Athletic/Workout Clothes 0.139 0.000 0.333
Bathing Suit 0.415 0.000 0.000
Casual 0.169 0.182 0.688
Dress Up 0.092 0.000 0.063
Alone 0.646 0.000 0.182
With Other People 0.169 0.000 0.182
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Table 6 – Readership Data 
Note: The data provided below is readership data for each magazine in which firms placed advertisements in.  This data is aggregate 
data  
Year Magazine Female Black Asian Other Hispanic White
1997               
 Glamour 78.82% 13.60% 2.37% 6.15% 11.65% 68.60% 
 Woman’s Day 82.51% 9.88% 0.56% 2.43% 6.70% 80.99% 
        
1998               
 Glamour 84.45% 13.41% 3.79% 4.68% 14.83% 67.08% 
 McCall’s-Rosie 84.95% 11.95% 1.59% 2.12% 8.52% 77.41% 
 Woman’s Day 85.66% 9.91% 1.55% 2.10% 6.65% 81.35% 
        
1999               
 
Better Homes and 
Garden 78.62% 11.07% 2.57% 3.24% 7.95% 77.74% 
 Cosmopolitan 80.78% 11.20% 2.88% 3.98% 15.63% 69.18% 
 Family Circle 90.29% 8.04% 1.16% 1.83% 7.35% 82.77% 
 Glamour 87.28% 12.99% 3.25% 4.43% 14.84% 67.73% 
 McCall’s-Rosie 88.44% 10.97% 1.61% 2.37% 9.48% 77.18% 
 Newsweek 46.94% 10.30% 4.35% 5.13% 9.10% 75.47% 
 People 66.48% 9.96% 2.75% 3.44% 10.94% 75.64% 
 Reader’s Digest 61.68% 9.45% 2.49% 3.21% 7.74% 79.60% 
 Sports Illustrated 23.63% 12.99% 2.29% 3.05% 11.78% 72.17%75353 
 Time 49.17% 12.15% 4.66% 5.45% 10.74% 71.67% 
 TV Guide 56.32% 15.24% 2.32% 3.05% 10.96% 70.75% 
 
US News and World 
Report 40.41% 9.70% 3.95% 4.58% 8.66% 77.07% 
 Vogue 80.68% 17.62% 5.42% 6.39% 15.23% 60.75% 
 Woman’s Day 93.07% 8.97% 1.40% 2.06% 7.55% 81.43% 
        
2000               
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Year Magazine Female Black Asian Other Hispanic White
2000 
(Cont)               
 
Better Homes and 
Gardens 79.69% 10.54% 2.55% 3.21% 9.94% 76.30% 
 Cosmopolitan 82.23% 10.59% 3.49% 4.14% 16.79% 68.49% 
 Family Circle 89.28% 8.01% 1.55% 2.19% 8.09% 81.70% 
 Glamour 87.19% 11.58% 4.16% 4.84% 14.72% 68.86% 
 Good Housekeeping 87.36% 10.69% 1.84% 2.44% 8.77% 78.10% 
 McCall’s-Rosie 89.37% 13.50% 1.95% 2.44% 8.79% 75.27% 
 Newsweek 46.15% 10.35% 4.57% 5.24% 10.27% 74.14% 
 People 67.36% 9.65% 3.50% 4.13% 11.66% 74.56% 
 Time 48.79% 10.80% 4.92% 5.79% 11.38% 72.03% 
 TV Guide 57.69% 13.77% 2.95% 3.66% 11.46% 71.11% 
 
US News and World 
Report 38.79% 11.32% 4.54% 5.32% 11.48% 71.88% 
 Woman’s Day 92.24% 9.81% 1.70% 2.27% 8.87% 79.05% 
        
2001               
 Cosmopolitan 83.80% 14.16% 3.77% 4.45% 15.36% 66.03% 
 Family Circle 91.67% 7.14% 1.37% 1.71% 8.58% 82.57% 
 Good Housekeeping 88.53% 10.01% 1.60% 2.21% 8.01% 79.77% 
 People 68.12% 8.43% 2.67% 3.08% 10.73% 77.75% 
 Rolling Stones 46.73% 9.77% 2.94% 3.65% 14.11% 72.47% 
 Sports Illustrated 22.57% 12.50% 2.43% 2.88% 10.64% 73.98% 
 Woman’s Day 94.15% 9.47% 1.80% 2.46% 7.55% 80.52% 
        
2002               
 People 69.98% 8.82% 3.16% 3.68% 10.31% 77.20% 
 Vogue 80.85% 17.98% 6.73% 7.53% 16.75% 57.74% 
 Woman’s Day 93.12% 8.06% 1.43% 1.97% 10.48% 79.49% 
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Table 6 
YEAR MAGAZINE FEMALE BLACK ASIAN OTHER HISPANIC WHITE 
LESS 
THAN 
HS 
GRAD 
HIGH 
SCHOOL 
GRAD 
SOME 
COLLEGE 
 AT LEAST 
COLLEGE 
GRADUATE 
1995                       
 Cosmopolitan 0.66 0.13 0.03 0.05 0.11 0.71 0.12 0.31 0.35 0.22 
 Glamour 0.74 0.15 0.03 0.05 0.11 0.69 0.14 0.33 0.32 0.21 
            
1996                       
 Cosmopolitan 0.68 0.13 0.03 0.05 0.11 0.71 0.12 0.31 0.35 0.22 
 Glamour 0.77 0.16 0.03 0.05 0.10 0.69 0.12 0.33 0.33 0.22 
            
1997                       
 Cosmopolitan 0.72 0.13 0.02 0.06 0.12 0.70 0.12 0.30 0.34 0.24 
 Glamour 0.79 0.14 0.02 0.06 0.12 0.69 0.13 0.31 0.33 0.24 
            
1998                       
 Cosmopolitan 0.78 0.11 0.04 0.05 0.15 0.69 0.13 0.30 0.34 0.23 
 Glamour 0.84 0.13 0.04 0.05 0.15 0.67 0.13 0.31 0.33 0.23 
            
1999                       
 Cosmopolitan 0.81 0.11 0.03 0.04 0.16 0.69 0.11 0.31 0.34 0.23 
 Glamour 0.87 0.13 0.03 0.04 0.15 0.68 0.12 0.30 0.34 0.24 
            
2000                       
 Cosmopolitan 0.82 0.11 0.03 0.04 0.17 0.68 0.13 0.32 0.33 0.23 
 Glamour 0.87 0.12 0.04 0.05 0.15 0.69 0.13 0.31 0.32 0.24 
            
2001                       
 Cosmopolitan 0.84 0.14 0.04 0.04 0.15 0.66 0.12 0.28 0.37 0.23 
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YEAR MAGAZINE FEMALE BLACK ASIAN OTHER HISPANIC WHITE 
LESS 
THAN 
HS 
GRAD 
HIGH 
SCHOOL 
GRAD 
SOME 
COLLEGE 
 AT LEAST 
COLLEGE 
GRADUATE 
2002                       
 Glamour 0.89 0.13 0.03 0.04 0.12 0.70 0.12 0.30 0.35 0.24 
            
 Cosmopolitan 0.82 0.10 0.03 0.04 0.15 0.70 0.10 0.33 0.33 0.24 
 Glamour 0.88 0.13 0.04 0.04 0.15 0.67 0.09 0.31 0.34 0.26 
            
2003                       
 Cosmopolitan 0.81 0.10 0.05 0.06 0.13 0.70 0.12 0.29 0.34 0.25 
 Glamour 0.87 0.12 0.05 0.06 0.12 0.70 0.10 0.31 0.35 0.25 
            
2004                       
 Cosmopolitan 0.84 0.09 0.05 0.07 0.12 0.72 0.08 0.27 0.37 0.27 
 Glamour 0.89 0.16 0.06 0.08 0.12 0.64 0.10 0.28 0.34 0.28 
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Table 6 (Continued) 
YEAR MAGAZINE 
Income 
Quintile 1 
Income 
Quintile 
2 
Income 
Quintile 
3 
Income 
Quintile 
4 
Income 
Quintile 5 
AGE       
18-24 
AGE       
25-39 
AGE       
40-64 AGE 65+  
1995                      
 Cosmopolitan 0.21 0.13 0.19 0.17 0.30 0.20 0.42 0.31 0.07  
 Glamour 0.23 0.14 0.17 0.16 0.30 0.25 0.43 0.28 0.04  
            
1996                      
 Cosmopolitan 0.22 0.14 0.18 0.16 0.30 0.22 0.42 0.28 0.08  
 Glamour 0.23 0.13 0.18 0.15 0.31 0.25 0.43 0.27 0.04  
            
1997                      
 Cosmopolitan 0.21 0.15 0.21 0.15 0.28 0.24 0.40 0.29 0.07  
 Glamour 0.22 0.15 0.20 0.14 0.28 0.25 0.42 0.27 0.06  
            
1998                      
 Cosmopolitan 0.22 0.21 0.17 0.17 0.23 0.23 0.39 0.31 0.06  
 Glamour 0.22 0.24 0.16 0.16 0.22 0.25 0.42 0.28 0.05  
            
1999                      
 Cosmopolitan 0.27 0.17 0.14 0.25 0.17 0.26 0.39 0.29 0.06  
 Glamour 0.26 0.17 0.14 0.24 0.19 0.27 0.41 0.26 0.05  
            
2000                      
 Cosmopolitan 0.23 0.20 0.10 0.26 0.21 0.28 0.38 0.28 0.06  
 Glamour 0.22 0.20 0.08 0.27 0.22 0.28 0.39 0.28 0.05  
            
2001                      
 Cosmopolitan 0.30 0.14 0.20 0.15 0.22 0.30 0.39 0.26 0.05  
 Glamour 0.29 0.14 0.22 0.15 0.21 0.26 0.43 0.26 0.05  
            
Gong 82 
YEAR MAGAZINE 
Income 
Quintile 1 
Income 
Quintile 
2 
Income 
Quintile 
3 
Income 
Quintile 
4 
Income 
Quintile 5 
AGE       
18-24 
AGE       
25-39 
AGE       
40-64 AGE 65+  
2002                      
 Glamour 0.29 0.14 0.18 0.14 0.25 0.31 0.36 0.30 0.03  
 Cosmopolitan 0.27 0.15 0.19 0.14 0.25 0.29 0.36 0.31 0.05  
            
2003                      
 Cosmopolitan 0.25 0.16 0.18 0.16 0.26 0.28 0.38 0.28 0.06  
 Glamour 0.24 0.17 0.18 0.16 0.25 0.27 0.39 0.30 0.04  
            
2004                      
 Cosmopolitan 0.20 0.22 0.21 0.12 0.25 0.27 0.37 0.31 0.05  
 Glamour 0.24 0.19 0.17 0.13 0.26 0.26 0.37 0.31 0.06  
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Table 7. 
MAG YEAR PRODUCT < 1 page 1 Page  MAG YEAR PRODUCT < 1 page 1 Page 
Cosmopolitan Total  15 101  Glamour   99 36 
 1988 Dexatrim2 0 2   1987 Thinz2 0 1 
    Grapefruit Herbal Diet2 0 2      Acutrim2 0 4 
    Trimolite 0 9    1989 Dexatrim2 0 3 
    Dietol-72 0 7    1993 Dexatrim2 0 2 
    Sure Cure2 7  0      Thermo Blend Fat Burner 2  0 
    Total Diet Plan2 0 3      Citrium 1  0 
    Cal-Ban 3000 0 7      Citramax 2  0 
    Acutrim2 0 5      Super Diet Max 2  0 
    Sure Cure II 2  0      CitriGold 1  0 
    Dexavall 2001 0 2      Ellotrim 1  0 
    The Final Diet  0 2      Citramax Plus 3  0 
    Successfully Slim 1  0    1996 Dexatrim2  0 2 
    Bio-Trim  0 2      Six Day Bio Diet 3  0 
    Nutrim 1  0      Thermo Blend Fat Burner 11  0 
    Maximum Weight-Loss Diet Plan  0 1      Chroma Slim 3 1 
  1989 Trimolite  0 4      Chromatrim 1  0 
    Sure Cure2 1 2      Citrus Slim 1  0 
    Cal-Ban 3000  0 3      Fat Burner  0 4 
  1990 Dexatrim2  0 3      Metrim  0 1 
    Cal-Ban 3000  0 1      Citralean 1  0 
    SIO  0 1      Energy Diet 1  0 
  1991 Dexatrim2  0 4      Bio-Safe 2  0 
  1992 Dexatrim2  0 4    1997 Thermo Blend Fat Burner 1  0 
  1993 Dexatrim2  0 1      Chroma Slim  0 2 
    Cybertrim  0 1      Ellotrim 3  0 
    Acu-Stop 2000  0 2      Bio-Safe 6  0 
    Lipo/Trim  0 3      Body Sculpture 4  0 
    Quick Trim  0 3    1998 Six Day Bio Diet 10  0 
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    Diet Max  0 2      Ellotrim 2  0 
    Cellulite Reduction System  0 1      Chromaslim Ultra  0 4 
    Metatrol 1  0      Insta-Slim Gold 2  0 
MAG YEAR PRODNUM < 1 page 1 Page  MAG YEAR PRODNUM < 1 page 1 Page 
 Cosmopolitan 1993 Chromalite 3  0 1   Glamour  1998 Celebrity Diet 1  0 
  Nutrition 21  0 1    48 Hour Miracle Diet 1  0 
    LipoTrim  0 3      Chromaslim Ultra  0 1 
  1994 Chromatrim 1  0      Ultrapyruvate  0 1 
    Quick Trim  0 2      Fat Assassin  0 1 
    Chromalite 3  0 1      Thyrolean 2  0 
    Ultra Diet Pep  0 2      Slimtan 1  0 
    Body Gold 1  0      Power Diet System 1  0 
    Cybergenic Quick Trim System  0 1      Lean Routine 1  0 
  1995 Dexatrim2  0 1      Weight Management System 1  0 
    Chroma Slim  0 3      Chitosan 3  0 
    Metrim  0 1      Cheat & Eat 1  0 
    Lipo/Trim  0 2      FTF 1  0 
    Meditrol  0 2       
    Stay Trim  0 1       
    Theraslim  0 1       
  1996 Ultra Diet Pep  0 1       
  2001 CarbSolutions  0 1       
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Figure 1: Frequency of Over-the-Counter Advertisements by Magazine
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Figure 2: Appearance of Prescription DTC Weight-Loss Products by Magazine
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Figure 3: Frequency of Over-the-Counter Advertisements by Year
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Figure 4: Frequency of Prescription Advertisements by Year
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Figure 5: Analysis of Firms' Placement of Over-the-Counter Advertisements by Year (1985-2002)
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Figure 6. Nature of Appeal within Advertisements
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Figure 7: Dissemination of Effectiveness Information by Target Audience
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Figure 8: Manner of Presentation of Effectiveness Data by Target Audience
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The figure above presents the only the advertisements that presented effectiveness information.  Consequently, because prescription 
DTC advertisements did not present any clinical or anecdotal data the frequencies are 0.   
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Figure 9: Use of Mechanism Information
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Figure 10: Frequency of Risk Information within Advertisements
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Figure 11: Use of Risk and Benefit Information
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Figure 12: Safety Claims And Product Differentiation Claims
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Figure 13a: Frequency of Advertisements Under 1 Page in Cosmopoitan and Glamour by Year
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Figure 13b: Frequency of Advertisements Longer than 1 Page in Cosmopoitan and Glamour 
by Year
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Appendix 1 – Events and Developments Regarding the Advertising of Weight-loss Products 
1962 – Federal Trade Commission transferred authority of regulating prescription drug 
advertising to the Food and Drug Administration with the amendment to the Food, Drug, 
Cosmetic Act (Calfee, 2002). 
1982 – FDA declared a moratorium on direct to consumer advertising after previously 
announcing that DTC advertising was not in violation of the FDA law and regulations 
(Calfee, 2002). 
1985 – FDA lifted its moratorium on DTC advertisements, but required DTC advertisements to 
meet the same standards as direct to physician advertisements (Calfee, 2002). 
1994 – Dietary Supplement Health and Education Act of 1994 shifted the burden of proving the 
safety of a dietary supplement from the FDA to the manufacturer (Blanck et al., 2001; 
Cleland et al., 2002). 
1996 – Dexfenfluramine and Fenfluramine were voluntarily withdrawn from the market after 
reports of heart valve abnormalities and an increased risk of pulmonary hypertension. 
1997 – FDA releases guidelines for DTC broadcast advertisements, which relaxed the 
requirements to provide disclosure information (Calfee, 2002). 
 
FDA proposed restrictions regarding the use of products containing Ephedrine Alkaloids 
(Clapham et al., 2001) 
 
Knoll releases its new product Sibutramine (Meridia), an appetite suppressant (Blanck, 
Khan, & Serdula, 2004a). 
1999 – Roche releases Orlistat (Xenical) (Blanck, Khan, & Serdula, 2004a). 
2000 – Manufacturers using the active ingredient phenylpropolamine voluntarily withdrew their 
products from the market after reports of an increased risk of hemorrhagic stroke 
(Clapham et al., 2001) 
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Appendix 2 – SCADS Archive 
The SCADS archive is a collection originally containing all print advertisements for 
smoking cessation products, tobacco products, and smoking-related public service 
announcements that appeared in 26 consumer magazines.  The archive was expanded to include 
weight-loss product advertisements in these same 26 magazines, which includes: Better Homes, 
Cosmopolitan, Esquire, Family Circle, Glamour, Good Housekeeping, Jet, McCall, Modern 
Maturity, Newsweek, People, Playboy, Readers Digest, Rolling Stone, Sports Illustrated, Time, 
TV Guide, Vogue, and Women’s Day.  Yearly Subscription data obtained from the Simmons 
National Consumer Survey for each magazine was used to fully describe the readership in terms 
of gender, race, ethnicity, education and income level.   
The original archive recorded print advertisements for weight-loss products between 
January 1985 and May 2002, which introduces 12 years of over-the-counter product 
advertisements that do not have prescription competitors.  Consequently, in order to compare the 
firm print advertising decisions, the over-the-counter print advertisements were limited to only 
periods when a name-brand prescription product was available, which occurs after January 1997.   
The SCADS database also includes print advertisements directed at physicians.  These 
advertisements were collected from the Journal of American Medical Association and the New 
England Journal of Medicine between January 1995 and May 2002.  Advertisements were 
collected on three brands: Redux, Meridia, and Xenical.  As stated in the data and methods 
section, the majority of the advertisements from the Journal of American Medical Association 
were missing form the bound copies in the library.  Upon further inquiry, the index of 
advertisements listed these products as “Demographic and “Mini” inserts an/or ROB ad pages.”  
Consequently, we cannot account for the claims made in these advertisements.   
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Over-the-counter Weight-Loss Products 
1EZDIET 
AMINOSCULPT 
ATKINS 
AUTOMATICWEIGHT-
LOSSCOMPOUND 
BDI Pharmaceuticals 
BETALEAN 
BETALEANHP 
Biomince 
BioSafe 
Biotrim 
Blast Away Fat 
Bodi-Trim 
Body Gold 
Body Sculpture 
BODYFORLIFE 
BODYSUCCESSDIET 
Cal-Ban 3000 
CARBCUTTER 
CARBSOLUTIONS 
Celebrity Diet 
Cellulite Reduction System 
CHANGEONEDIET 
Cheat and Eat 
CHEATTABS 
CHINESEDIETTEA 
Chitosan 
Chromaslim 
Chromaslim Ultra 
Chromatrim 
Chromax 
Chromax 
Chromium Picolinate 
Chromolite 3 
Citralean 
CitriGold 
Citrimax 
Citrimax Plus 
Citrium 
Citrusslim 
CORDUZIN 
CORTISLIM 
Curves 
Cybertrim 
D and E Pharmaceuticals 
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Definition 
Dexatrim 
Dexatrim Extra Strength 
Dexatrim Maximum Strength 
DEXATRIMNATURAL 
Dexavall 2001 Plan 
Diet Aids 
Diet Pills and Energizers 
DIETFUEL 
DietMax 
Dietol-7 
Ellotrim 
ELUSLIM 
Energy diet 
ESTROLEAN 
Fat Assassin 
Fat Burner 
Fat Control 
Final Diet 
Fit Over 40 System 
FTF 
GELATHIN 
GLUCOtherM 
Grapefruit Herbal Diet 
HUNGERSWITCH 
HYDROGELSLIMPATCH 
HYDROXYCUT 
Inhibitol 
Insta-Slim Gold 
Lean Routine 
LEANBALANCE 
LEANSOURCE 
LEANSYSTEM7 
LEANTABS 
LIPOBAN 
Lipotrim 
LIVLITE 
MAGGIEDROZD-WEIGHTLOSSPLAN 
Maximum Loss Diet Plan 
MEDIFAST 
Meditrol 
MELTRX 
Metatrol 
Metrim 
MIAMI48HOURDIET 
MONTIGNACWEIGHT-LOSSPLAN 
More Than A Diet 
MYOPLEX 
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MYOPLEXSPORT 
Nutrim 
NUTRISYSTEMNOURISH 
Nutrition 21 
NX Trim 
ONE-A-DAYWEIGHT 
ONE-A-DAY WEIGHT SMART 
ORIGINALCELEBRITYJUICEDIE
T 
ORIGINALHOLLYWOODCELEB
RITYDIET 
ORIGINALHOLLYWOOODDIETJ
UICE 
OXYLENE 
PATENTLEAN 
PEDIALOSS 
Pepback 
Phase I 
Power Diet System 
Prolamine 
Prolamine 
Prolamine 
PURANOL 
Quick Trim 
QUICKSLIM 
RAPID WEIGHT LOSS 
RELACORE 
Revive 
SATISE 
SHAPEUP 
Sio 
Six Day Bio Diet 
SKINNYPILL 
SLIMFAST 
SLIMFASTOPTIMA 
SLIMFASTPLAN 
SLIMMINTS 
Slimtan 
STACKER2 
STARCHAWAY 
Stay Trim 
Successfully Slim 
Super Diet Max 
Super Formula 
Sure Cure 
Sure Cure II 
Svelt Patch 
Synedrex 
TAEBOENDPOWERDIET 
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TETRAZENE 
The Milford Plan 
Theraslim 
THERMAFEM 
Thermo Blend 
THERMODYNAMX 
THERMOINFUSION 
Thermotrim 
Thinz 
Thyrolean 
Thyrolean 
Tonalin 
Tonalin 
Total Diet Plan 
TOTALLEAN 
Trimolite 
TRIMSPAX32 
TRIOMEGA 
TRIPLELEAN3 
TUMMYFLATTENING-GEL 
Ultimate Solution Diet Program 
Ultra Diet Pep 
Ultra Pyruvate 
ULTRACARB 
ULTRALIPOLEAN 
ULTRAPERFECT 
VITRACIN 
WEBMDWEIGHTLOSS 
Weight Management System 
WEIGHTLOSSPILLS 
WEIGHTWATCHERS 
XENADRINE 
Xenadrine EFF 
XENADRINE40 
XENADRINEEFX 
XENADRINE HIGH PROTEINBAR 
XENADRINENRG 
ZANTREX3 
ZOTRIN
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Appendix 3: Over-the-Counter Weight-Loss Coding Form 
CONTENT CODING FORM FOR OTC WEIGHT LOSS 
 
UNIQUE AD NUMBER ____________________ UANUM 
Product __________________________ 
Product Number_______ PRODNUM 
Manufacturer  ____________________________      
Manufacturer Number _______ MANUMN                             
 
     (Ad Length) 
     □<1pgs   How big (Width X Length in inches): ________ WIDTH X________ 
LENGTH 
     □1pg                                     
     □>1pgs   How many pages:________________ NUMPAGES 
 
 Product Type    
   □ Not specified PRODTYPENS 
   □ (Tablet)     □ (Gum)     □ (Bar)    □ (Capsule)   □ (Caplet)   □ (Shake/Liquid)  □ (Gel) 
   □ (Patch)      □ (Cream)      □ Unspecified Pill (Not identified as tablet, capsule, or 
caplet) PILLUS 
□ Other PRODTYPEO ___________ PRODTYPEOT 
            
Design of Ad ADDESIGN 
                  □ Color                  □ Black & White                   □ Microfiche 
 
Ad Visual  (check all that apply) 
     □ (Picture)                  □ (Product)                  □ (Text)                  □ (Chart/graph)           
     □ (Questionnaire)       □ (Cutout)                   □ (Testimonial)       
 
Taglines  
            □ None specified 
            □ Tagline:___________________________________________ 
                              Number:______ TAGNUM 
Directives  (check all that apply)   
□ None specified  DIRECTNS 
□ Order:          □ Now DIRECT1         □ By phone DIRECT2     □ By Mail DIRECT3       
□ Other: DIRECT4 _____________ DIRECT4OT         
□ Use with a sensible diet and exercise plan DIRECT5 
□ Take before meals DIRECT6 
□ Consult your physician before using DIRECT7 
         □ especially if you have high blood pressure, if pregnant or nursing, or on 
medication   
            for heart condition or taking a MAO inhibitor DIRECT8 
□ If you lose too much weight, use product less often DIRECT9 
□ This product is not intended to diagnose, treat, cure or prevent any disease DIRECT10 
Gong 106 
□ You need to measure your results weekly to prevent excessive weight loss DIRECT11 
□ This product is not for use by individuals under the age of 18 DIRECT12 
□ Use only as directed DIRECT13 
□ Other ___________________________ DIRECTOT           
Side Effects  (check all that apply) 
                 □ none specified SIDENS 
                 □ reduces the absorption of vitamins SIDE1 
                 □ lose weight too fast SIDE2 
                 □ Other: _______________________________ SIDEOT 
General Claims  (check all that apply) 
   
General Claims 
□ Scientifically formulated/patented technology GCLAIM1 
□ Clinically tested/studied GCLAIM2 
□ Finally available in US GCLAIM3 
□ Ingredients patented GCLAIM4 
□ New discovery/ Discovery in exotic locale GCLAIM5 
□ As seen on T.V. GCLAIM6 
□ Available at food, drug and discount stores GCLAIM7 
□ Great Taste GCLAIM8 
□ Sugar Free GCLAIM9 
 
Negative General Claims 
□ These statements have not been evaluated by the Food and Drug Administration 
NGCLAIM1 
□ Results not typical and depend on your diet and training program./Individual results 
may vary NGCLAIM2 
□ Alters the way your body digests food NGCLAIM3 
 
Fat/Cholesterol/Muscle                                          
□ Detoxifies body FAT1 
□ Burns/oxidizes/reduces/inhibits production of fat, converts fat into energy FAT2 
□ Burns Calories FAT3 
□ Stabilizes blood sugar FAT4 
□ Reduces cholesterol/triglycerides FAT5 
□ Tones muscle, increases muscle tissue, converts amino acids to muscle FAT6 
□ Gets rid of flab FAT7 
□ Blocks calorie absorption FAT8      
□ Reduces cellulite FAT9  
                                                                                
Nutrients/Metabolism 
□ Provides essential nutrients NUTRIENT1 
□ Does not interfere with the normal absorption of vitamins and minerals NUTRIENT2 
□ 100% all natural/ contains no drugs NUTRIENT3 
□ Non-addictive/ contains no caffeine or chemical stimulant NUTRIENT4 
□ Does not upset metabolism NUTRIENT5 
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□ Increases metabolism/metabolic rate NUTRIENT6 
□ Regulates metabolism  NUTRIENT7 
□ Replaces a meal   NUTRIENT8 
□ Absorbs water NUTRIENT9 
□ Doesn’t ruin a low-carb diet NUTRIENT10 
□ Contains:  
                   □ The GAFA Complex NUTRIENT11 
                   □ Chromium Picolinate NUTRIENT12 
                   □ Pyruvate NUTRIENT13 
                   □ Other: __________________________________________ 
NUTRIENT14 
□ Prevents the absorption of carbohydrates and helps them from being converted to fat 
NUTRIENT15 
□ L-Camatine included NUTRIENT16 
□ Rids your body of toxins NUTRIENT17 
                                                               
Miraculous Claims 
□ (Proven) effective MIRACLE1 
□ Guaranteed results MIRACLE2 
□ Results can be seen almost immediately/ fast acting MIRACLE3 
□ Boosts strength, energy, and libido MIRACLE4 
□ Appetite suppressant/ controls hunger MIRACLE5 
□ Lose   ____ lbs   in ____   days /weeks/ months (circle 
one)  
MIRACLE6  MIRACLE6A  MIRACLE6C   MIRACLE6B 
□ Sent discreetly MIRACLE7 
□ Dramatic results are not uncommon MIRACLE8 
□ This patented product works well for both men and women MIRACLE9 
□ Endorsement by doctor MIRACLE10 
□ Safe for diabetics/ Stabilize blood sugar MIRACLE11 
□ Helps improve the normal functions of your body MIRACLE12 
□ Lose ___________ inches from ________(i.e. each thigh) in ______          
days/weeks/months  
        MIRACLE13A                MIRACLEB                         MIRACLE13C     
MIRACLE13D 
        □ Additional claims:  
□ Lose ___________ inches from ________(i.e. each thigh) in ______          
days/weeks/months  
        MIRACLE14A                MIRACLE14B                         MIRACLE14C     
MIRACLE14D 
□ Lose_______ % of the fat layer from stomach/ body fat in _______         
days/weeks/months MIRACLE15A      
 MIRACLE15B       MIRACLE15C 
□ Went from size ______ to   size ______ OR  Lose ________ sizes 
  MIRACLE16A  MIRACLE16B  MIRACLE16C 
□ Controls your weight/ do not gain weight back MIRACLE17 
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□ 100% risk free MIRACLE18 
□ Can be taken while on medication MIRACLE19 
□ Highly recommended by European doctors MIRACLE20 
□ Can help in reducing and eliminating both early stretch marks and late stretch marks 
 MIRACLE21 
□ Can lose weight without counting calories/exercise MIRACLE22 
□ Medical Breakthrough MIRACLE23 
□ Fat Burner AND tan accelerator MIRACLE24 
□ Can eat anything you want! MIRACLE25 
□ Makes you feel good about yourself MIRACLE26 
  Offerings (check all that apply) 
 □ None specified OFFERNS 
 □ Coupons and discounts OFFER1 
 □  Free Gift OFFER2 
                  □Type of gift:___________________________________  OFFER2T 
 □ Money back guarantee OFFER3 
                   □ Conditions: ___________________________________  OFFER3T 
                   □ No conditions specified OFFER3NS 
 □ Order form OFFER4 
 □ Support program OFFER5 
□ Fitness system/Nutritional Plan OFFER6 
□ Free trial offer/free sample OFFER7 
□ Special Bonus OFFER8 
□ Other ____________________________________ OFFERO 
Pricing (fill in the blanks and check all that apply)  
   □ No pricing information specified PRICEN              □ Credit Cards accepted 
PRICECC 
 
  PRICE1A  PRICE1B  PRICE1C          PRICE2A          PRICE2B  PRICE2C 
□ $_____.___ for a  □ ______ day supply    □ $_____.___ for a  □ ______ day supply 
                                 □ ______ week supply                                  □ ______ week 
supply 
                                 □ ______ month supply                               □ ______ month 
supply 
                                 □______ pill supply                                      □______ pill supply  
                                    □ not specified supply                                  □ not specified supply 
  PRICE3A  PRICE3A  PRICE3C        PRICE4A            PRICE4B  PRICE4C 
□ $_____.___ for a  □ ______ day supply    □ $_____.___ for a  □ ______ day supply 
                                 □ ______ week supply                                  □ ______ week 
supply 
                                 □ ______ month supply                               □ ______ month 
supply 
                                 □______ pill supply                                      □______ pill supply  
                                    □ not specified supply                                   □ not specified supply 
 
□ Shipping & Handling Information:_______________________________________ 
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  SHIPPING 
 
Contact Information (check all that apply) 
 
      □ No additional information     □ Address         □ Phone Number               
 CONTACTN           CONTACT1       CONTACT2 
      □ Website       
       CONTACT3 
               □ Other________________________________                                   
                     CONTACTO 
Nature of Ad Appeal (check all that apply) 
□ Anecdotal/Testimonial APPEAL1 
□ Sex appeal APPEAL2 
□ Safety/ Health & Nutrition APPEAL3  
□ Motivational/Optimistic  APPEAL4 
□ Informative/Statistics & Studies APPEAL5 
□ Fear Based APPEAL6 
□ Promotional APPEAL7 
□ Humor/Witty APPEAL8 
□ Emotional APPEAL9 
□ Stressing Activity or Exercise APPEAL10 
□ Celebrity Appeal APPEAL11 
□ Popular APPEAL12 
□ Best Selling APPEAL13 
If Best Selling or Popular, how many products sold:  
                           □ Thousands APPEAL13A 
                           □ Millions APPEAL13B 
                           □ Specific Number:____________________________ APPEALC 
 
Superiority Claims          
                               □ None SUPERNS 
  
            □ Comparison Product(s) SUPERP              □ General Comparison SUPERG 
   Which Product:______________________ SUPERPW 
   Basis of Comparison:__________________ SUPERPB 
   Text of claim______________________________________________________ 
  SUPERPT     ______________________________________________________    
 
Before and After Pictures 
 
Are there Before/After Full Person pictures:      □ Yes                          □ No 
                BANDAY 
            If yes, how many before and after full person sets are in ad:_________________ 
         BANDANUM 
1st Set of before/after pictures: 
 BANDA1RACE    Race    □ White    □ Black    □ Hispanic    □ Asian    □ Other      □ 
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CBI 
 BANDA1GENDER  Gender   □ Male       □ Female                                                   □ 
CBI 
 BANDA1AGE    Age        □ Child       □ Teen      □ Adult          □ Elder                   □ 
CBI     
 BANDA1USE    Using Product           □ Yes        □ No      
 BANDA1TIME    Time on product: __________________   □ N/A  BANDA1NA 
                   Celebrity:     □ Yes        □ No     If Yes, Who:________________________  
     BANDA1CELEB  BANDA1CELEBWHO 
 Weight before:_________  Weight after:_________ Total Weight Lost:____________ 
BANDA1WB   BANDA1WA   BANDA1WT 
    Demeanor: 
BANDA1DIMB   Before:  □ Sad/Stern    □ No particular expression    □ Happy/Smiling 
 
BANDA1DA       After:    □ Sad/Stern     □ No particular expression    □ Happy/Smiling 
    Clothing:  
 BANDA1CB   Before:  □ Bathing Suit  □ Athletic/workout clothes   □ Casual   □ Dress 
up 
  
 BANDA1CB   After:  □ Bathing Suit  □ Athletic/workout clothes   □ Casual   □ Dress 
up 
 
    Social Depiction: 
 BANDA1SDB   Before:  □ Alone    □ With other people   
If with other people   BANDA1SDWHOB 
□ Family    □ Romance  □ Work    
□ Recreation □ Other ______________________      
             
 BANDA1SDA   After:    □ Alone    □ With other people                    
If with other people  BANDA1SDWHOA  
□ Family    □ Romance  □ Work    
□ Recreation □ Other ______________________ 
 
2nd Set of before/after pictures: 
 
BANDA2RACE    Race    □ White    □ Black    □ Hispanic    □ Asian    □ Other      □ 
CBI 
 BANDA2GENDER  Gender   □ Male       □ Female                                                   □ 
CBI 
 BANDA2AGE    Age        □ Child       □ Teen      □ Adult          □ Elder                   □ 
CBI     
 BANDA2USE    Using Product           □ Yes        □ No      
 BANDA2TIME    Time on product: __________________   □ N/A  BANDA2NA 
                   Celebrity:     □ Yes        □ No     If Yes, Who:________________________  
     BANDA2CELEB  BANDA2CELEBWHO 
 Weight before:_________  Weight after:_________ Total Weight Lost:____________ 
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BANDA2WB   BANDA2WA   BANDA2WT 
    Demeanor: 
BANDA2DB   Before:  □ Sad/Stern    □ No particular expression    □ Happy/Smiling 
 
BANDA2DA       After:    □ Sad/Stern     □ No particular expression    □ Happy/Smiling 
    Clothing:  
 BANDA2CB   Before:  □ Bathing Suit  □ Athletic/workout clothes   □ Casual   □ Dress 
up 
  
 BANDA2CB   After:  □ Bathing Suit  □ Athletic/workout clothes   □ Casual   □ Dress 
up 
 
    Social Depiction: 
 BANDA2SDB   Before:  □ Alone    □ With other people   
If with other people   BANDA2SDWHOB 
□ Family    □ Romance  □ Work    
□ Recreation □ Other ______________________      
             
 BANDA2SDA   After:    □ Alone    □ With other people                    
If with other people  BANDA2SDWHOA  
□ Family    □ Romance  □ Work    
□ Recreation □ Other ______________________ 
   3rd  Set of before/after pictures: 
 BANDA3RACE    Race    □ White    □ Black    □ Hispanic    □ Asian    □ Other      □ 
CBI 
 BANDA3GENDER  Gender   □ Male       □ Female                                                   □ 
CBI 
 BANDA3AGE    Age        □ Child       □ Teen      □ Adult          □ Elder                   □ 
CBI     
 BANDA3USE    Using Product           □ Yes        □ No      
 BANDA3TIME    Time on product: __________________   □ N/A  BANDA3NA 
                   Celebrity:     □ Yes        □ No     If Yes, Who:________________________  
     BANDA3CELEB  BANDA3CELEBWHO 
 Weight before:_________  Weight after:_________ Total Weight Lost:____________ 
BANDA3WB   BANDA3WA   BANDA3WT 
    Demeanor: 
BANDA3DIMB   Before:  □ Sad/Stern    □ No particular expression    □ Happy/Smiling 
 
BANDA3DA       After:    □ Sad/Stern     □ No particular expression    □ Happy/Smiling 
    Clothing:  
 BANDA3CB   Before:  □ Bathing Suit  □ Athletic/workout clothes   □ Casual   □ Dress 
up 
  
 BANDA3CB   After:  □ Bathing Suit  □ Athletic/workout clothes   □ Casual   □ Dress 
up 
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    Social Depiction: 
 BANDA3SDB   Before:  □ Alone    □ With other people   
If with other people   BANDA3SDWHOB 
□ Family    □ Romance  □ Work    
□ Recreation □ Other ______________________      
             
 BANDA3SDA   After:    □ Alone    □ With other people                    
If with other people  BANDA3SDWHOA  
□ Family    □ Romance  □ Work    
□ Recreation □ Other ______________________ 
_______________________________________________________________________
__ 
Complete this section if there are BODY PARTS depicted in the ad.  
 
Body Parts shown:             □ Yes                    □ No 
 BPARTSYN 
 
 
 
Check all that apply:    
  
Person 1:       □ Torso          □ Arms           □ Legs            □ Back             □ 
Other__________ 
           BPARTS1A   BPARTS1B   BPARTS1C    BPARTS1D   BPARTS1O 
□ Before and after body part picture for Person 1 BPARTSBA 
 
REPEAT CODES 
Person 2:       □ Torso          □ Arms              □ Legs          □ Back       □ 
Other__________ 
□ Before and after body part picture for Person 2 
 
Person 3:       □ Torso          □ Arms              □ Legs           □ Back      □ 
Other__________ 
□ Before and after body part picture for Person 3 
 
Person 4:       □ Torso          □ Arms              □ Legs           □ Back      □ 
Other__________ 
□ Before and after body part picture for Person 4 
 
Person 5:       □ Torso          □ Arms              □ Legs           □ Back      □ 
Other__________ 
□ Before and after body part picture for Person 5 
 
_______________________________________________________________________
__ 
If there are NO before-after pictures in the ad but there ARE pictures of people, 
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complete the following sections 
 
Person 1    
P1RACE        Race      □ White      □ Black     □ Hispanic     □ Asian     □ Other    □ CBI 
P1GENDER  Gender   □ Male       □ Female                                                               □ 
CBI 
P1AGE          Age        □ Child       □ Teen      □ Adult          □ Elder                          □ 
CBI     
P1USE          Using Product           □ Yes        □ No      
P1WLOSS    Weight lost (in lbs):_______                                              □ N/A 
P1WLOSSNA   
P1TOPNUM  Time on product: ________  Time Unit_______ P1TOPT   
P1CELEB      Celebrity:     □ Yes        □ No     If Yes, Who:_____________ 
P1CELEBWHO 
P1OCCU        Occupation, if stated:_____________________________________ 
                   Weight before:_______  Weight after:_______ Total Weight Lost:________ 
  P1WLOSSB  P1WLOSSA  P1WLOSST 
P1D   Demeanor:       □ Sad/Stern         □ No particular expression       □ Happy/Smiling    
 
P1C    Clothing:    □ Bathing Suit   □ Athletic/workout clothes     □ Casual       □ Dress 
up 
  
P1SD     Social Depiction:      □ Alone    □ With other people                    
If with other people   P1SDWHO 
□ Family    □ Romance  □ Work    
□ Recreation □ Other ______________________ 
         
Person 2     Race      □ White      □ Black     □ Hispanic     □ Asian     □ Other        □ 
CBI 
REPEAT CODES  Gender   □ Male       □ Female                                                 □ CBI 
                   Age        □ Child       □ Teen      □ Adult          □ Elder                          □ CBI    
                   Using Product           □ Yes        □ No      
                   Weight lost (in lbs):_______                                                                  □ N/A   
                   Time on product: __________________                                               □ N/A    
                   Occupation, if stated:_____________________________________ 
                   Celebrity:     □ Yes        □ No     If Yes, Who:________________________ 
      Weight before:_______  Weight after:_______ Total Weight Lost:________ 
    Demeanor: 
            □ Sad/Stern         □ No particular expression       □ Happy/Smiling      
Clothing:    □ Bathing Suit   □ Athletic/workout clothes     □ Casual       □ Dress up  
     Social Depiction: 
             □ Alone    □ With other people                    
If with other people    
□ Family    □ Romance  □ Work    
□ Recreation □ Other ______________________ 
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Person 3     Race      □ White      □ Black     □ Hispanic     □ Asian     □ Other        □ 
CBI 
                   Gender   □ Male       □ Female                                                               □ CBI 
                   Age        □ Child       □ Teen      □ Adult          □ Elder                          □ CBI    
                   Using Product           □ Yes        □ No      
                   Weight lost (in lbs):_______                                                                  □ N/A   
                   Time on product: __________________                                               □ N/A  
                   Occupation, if stated:_____________________________________ 
                   Celebrity:     □ Yes        □ No     If Yes, Who:________________________ 
  
                  Weight before:_______  Weight after:_______ Total Weight Lost:________ 
    Demeanor: 
            □ Sad/Stern         □ No particular expression       □ Happy/Smiling       
     Clothing:    □ Bathing Suit   □ Athletic/workout clothes     □ Casual       □ Dress up 
     Social Depiction: 
             □ Alone    □ With other people                    
If with other people    
□ Family    □ Romance  □ Work    
□ Recreation □ Other ______________________ 
 
Person 4     Race      □ White      □ Black     □ Hispanic     □ Asian     □ Other        □ 
CBI 
                   Gender   □ Male       □ Female                                                               □ CBI 
                   Age        □ Child       □ Teen      □ Adult          □ Elder                          □ CBI    
                   Using Product           □ Yes        □ No      
                   Weight lost (in lbs):_______                                                                  □ N/A   
                   Time on product: __________________                                               □ N/A  
                   Celebrity:     □ Yes        □ No     If Yes, Who:________________________  
                   Occupation, if stated:_____________________________________                 
                   Weight before:_______  Weight after:_______ Total Weight Lost:________ 
    Demeanor: 
            □ Sad/Stern         □ No particular expression       □ Happy/Smiling       
Clothing:    □ Bathing Suit   □ Athletic/workout clothes     □ Casual       □ Dress up 
     
     Social Depiction: 
             □ Alone    □ With other people                    
If with other people    
□ Family    □ Romance  □ Work    
□ Recreation □ Other ______________________ 
Person 5     Race      □ White      □ Black     □ Hispanic     □ Asian     □ Other        □ 
CBI 
                   Gender   □ Male       □ Female                                                               □ CBI 
                   Age        □ Child       □ Teen      □ Adult          □ Elder                          □ CBI    
                   Using Product           □ Yes        □ No      
                   Weight lost (in lbs):_______                                                                  □ N/A   
                   Time on product: __________________                                               □ N/A  
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                   Celebrity:     □ Yes        □ No     If Yes, Who:________________________  
                   Occupation, if stated:_____________________________________ 
                   Weight before:_______  Weight after:_______ Total Weight Lost:________ 
    Demeanor: 
            □ Sad/Stern         □ No particular expression       □ Happy/Smiling      
    Clothing:    □ Bathing Suit   □ Athletic/workout clothes     □ Casual       □ Dress up  
     Social Depiction: 
             □ Alone    □ With other people                    
If with other people    
□ Family    □ Romance  □ Work    
□ Recreation □ Other ______________________ 
Group of people (5 or more people) 
 
GROUPYES                  □ Group of people          □ No group of people 
GRACEW/B/H/A/O/CBI   Race   □ White   □ Black   □ Hispanic   □ Asian   □ Other   □ 
CBI  
GGENDERM/F/CBI  Gender   □ Male       □ Female                                                      □ 
CBI 
GAGEC/T/A/E/CBI Age        □ Child       □ Teen      □ Adult          □ Elder                   □ 
CBI   
GUSE       Using Product           □ Yes        □ No   
 
 Social Depiction:            
 □ Family       □ Romance        □ Work      □ Recreation            □ 
Other____________ 
 GFAMILY   GROMANCE    GWORK   GRECREATION      GSDOTHER 
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Appendix 4: Prescription Weight-Loss Coding Form 
CODING FORM FOR Prescription Weight-Loss 
 
UNIQUE AD NUMBER_________________ UNIQUEADNUMBER 
BRAND NUMBER _____________________  
PRODUCT ____________________________ PRODUCT 
MANUFACTURER _____________________ MANUFACTURER 
 
Type of ad                            □ Advertisement TYPEADVERTISEMENT   
(check all that apply)    □ Preview Ad TYPEPREVIEWAD 
    □ Other____________TYPEOFADOTHER 
Sponsors________________________________TYPEOFADSPONSORS 
 
Journal(s)/Magazines Found In 
______________________________JOURNALSMAGAZINES 
 
     Ad Length      Type of Advertisement 
     □1pg ADLENGTHN1PAGE   □ Help-Seeking 
TYPEOFADHELPSEEKING 
     □2pgs ADLENGTHN2PAGES    □ Reminder Advertisements   
       
 TYPEOFADREMINDERADVERTISEMENT 
     □3pgs ADLENGTHN3PAGES    □ Product name and disease info  
       
 TYPEOFADPRODUCTNAME 
     □4pgs ADLENGTHN4PAGES                                  
     □>4pgs ADLENGTHM4PAGES 
 
     Directive Length 
     □1pg DIRLENGTHN1PAGE   □ BMI Chart 
DIRECTIVEBMICHART 
     □2pgs DIRLENGTHN2PAGE   □ Side Effects Chart 
DIRSIDEEFFECTS 
     □3pgs DIRLENGTHN3PAGE   □ Healthy Diet Chart 
DIRHEALTHYDIET 
 
     FDA APPROVAL DATE 1_________ DIRLENGTHFDAAPPROVAL1 
     FDA APPROVAL DATE 2_________ DIRLENGTHFDAAPPROVAL2 
     FDA APPROVAL DATE 3_________ DIRLENGTHFDAAPPROVAL3 
     Product Type        □ Not Specified PRODTYPENOTSPECIFIED 
   □ Tablet        □ Capsule      
   PRODTYPETABLET PRODTYPECAPSULE 
   □ Program   □ Other____________________ 
   PRODTYPEPROGRAM PRODTYPEOTHER 
□ Dosage not specified  DOSAGENOTSPECIFIED 
      Dosage                 ______mg  □ n/a                    ______mg  □ n/a                     
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   DOSAGE1   DOSAGE2 
      Frequency         □D □W □M □O_____          □D □W □M □O_____         
FREQDAILY1/WEEKLY1/MONTHLY1/OTHER1          FREQDAILY2/WEEKLY2/MONTHLY2/OTHER2 
                                         □ not specified                         □ not specified                   
   FREQNOTSPECIFIED1                       FREQNOTSPECIFIED2 
                         ______mg  □ n/a                    ______mg  □ n/a                     
   DOSAGE3   DOSAGE4 
      Frequency         □D □W □M □O_____          □D □W □M □O_____         
FREQDAILY3/WEEKLY3/MONTHLY3/OTHER3          FREQDAILY4/WEEKLY4/MONTHLY4/OTHER4 
                                         □ not specified                         □ not specified                   
   FREQNOTSPECIFIED3                       FREQNOTSPECIFIED4 
 
      Manufacturer     
____________________________      
Number _______                                □  Unable to be determined   
     Design of Ad        □ Color   □ Black & White  □ Microfiche 
   DESIGNADCOLOR DESIGNADBLACKANDWHITE
 DESIGNADMICROFICHE 
     Ad Visual  (check all that apply)          
 Picture          □ Product         □ Text         □  
chart/quiz/questionnaire 
ADVISUALPICTURE ADVISUALPRODUCT ADVISUALTEXT 
 ADVISUALCHARTQUIZQUESTIONAIRE 
      (Tagline)      
________________________________________________________________________
___________ 
Font Type Description    TAGLINEFONTDESCRIPTION 
Number _____                                                               □ No tagline in ad 
     Administration     □ By prescription only  □ OTC (Over the Counter)      
   ADMINPRESCRIPTION 
 ADMINOVERTHECOUNTER 
                             □ Not identified in ad         ADMINNOTSPECIFIED 
        Directives  (check all that apply)            □ None specified 
  □ Ask/see doctor or healthcare professional DIRASKSEEDOCTOR 
  □ Tell your doctor about any problems you have with medication 
DIRTELLYOURDOCTOR 
  □ Avoid possible dangerous drug interactions DIRAVOIDPOSSIBLE 
  □ Use in conjunction with changes in diet and/or exercise DIRDIETEXERCISE 
  □ Follow dosing schedule (e.g. “once a day”) DIRFOLLOWDOSING 
  □ See important information on the following page 
DIRSEEIMPORTANTDIRECTIVEPAGE 
  □ Product is not for everyone DIRPRODUCTISNOT 
  □ Tell your physician if you are taking cyclosporine DIRTELLYOURPHYSICIAN 
  □ BMI > 30 or BMI > 27 with risk factors DIRBMIANDRISKFACTORS 
                  □ Other _____________________________ DIROTHER 
 
          Do Not Take If… 
  □ Hx of CAD DNTHXOFCAD                           □ Hx of Cardiac arrhythmias 
DNTHXOFCADIAC 
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  □ Hx of CHF DNTHXOFCHF                            □ Hx of stroke DNTHXOFSTROKE 
  □ Hx of poorly controlled hypertension              □ Hx of severe hepatic dysfunction       
     DNTHXOFPPOORLYHTN             DNTHXOFSEVEREHEPATIC 
  □ Hx of severe renal impairment DNTHXOFSEVERERENAL 
  □ Gall bladder problems DNTGALLBLADDER      □ Pregnant or breastfeeding 
DNTPREGNANTORNURSING 
  □ Food absorption problems                               □ Reduced bile flow 
     DNTFOODABSORPTIONPROB   
  □ Parkinson’s disease                                           □ Under 16 or  18 
     DNTPARKINSONSDISEASE    DNTUNDER16 DNTUNDER18 
  □ Hypersensitivity to Subutramine                      □ Anorexia nervosa  
      DNTHYPERSENSITIVITYSUBUTRAMINE  DNTANOREXIANERVOSA 
  □ Malabsorption syndromes                                 □ Organic causes of obesity (i.e 
hypothyroidism) 
      DNTMALABSORPTIONSYNROME   DNTORGANICCAUSESOFOBESITY 
  □ Allergies to product                                          □ Serious Heart Condition 
     DNTALLERGIESPROD    DNTSERIOUSHEARTCONDITION 
  □ Hx of Migraines                                                □ Glaucoma 
     DNTHXOFMIGRAINES    DNTGLAUCOMA 
  □ Taking other appetite suppressant drugs          □ Taking Cyclosporine  
     DNTTAKINGAPPETITESUPPRESANTS  DNTTAKINGCYCLOSPORINE 
               □ Other _____________________________DNTOTHER 
 
        Side Effects  (check all that apply)                       □ None specified 
SENONESPECIFIED 
□ Pulmonary hypertension                  □ Seizures                            □ Renal/hepatic 
dysfunction       
SEPULMONARYHYPERTENSION SESEIZURES   SERENALHEPATIC 
□ diarrhea                                          □ headaches                         □ Dry mouth 
SEDIARRHEA    SEHEADACHES  SEDRYMOUTH 
□ Loss of appetite                              □ Constipation                     □  Insomnia 
SELOSSOFAPPETITE   SECONSTIPATION  SEINSOMNIA 
□ Gallstones                                       □ gas w/ oily discharge       □  Increased bowel 
movements  
SEGALLSTONES   SEGASWOILYDISCHARGES SEINCREASEDBOWEL 
□ Reduced vitamin absorption □ Anorexia       □ Inability to control bowel 
movements 
SEREDUCEDVITAMIN   SEANOREXIA  SEINABILITYTOBOWELMOVE 
□ Interference with cognition and motor performance SEINTERFERENCEWCOGNITION 
          □ Other ___________________________________________ SEOTHER 
 
       General Claims (check all that apply)                    □ None specified 
EFFNONESPECIFIED 
Effectiveness 
  □ Provides sustained weight loss ___% and ____ years □ Graph/Chart   Dose 
_____    □ CS 
 EFFPROVIDESSUSTAINED1  EFFFORTIME1    EFFGRAPHCHART1
 EFFDOSE1 EFFCS 
  □ Provides sustained weight loss ___% and ____ years □ Graph/Chart  Dose 
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_____    □ CS 
 EFFPROVIDESSUSTAINED2  EFFFORTIME2    EFFGRAPHCHART2
 EFFDOSE2 EFFCS2 
  □ Provides sustained weight loss ___% and ____ years □ Graph/Chart  Dose 
_____    □ CS  
 EFFPROVIDESSUSTAINED3  EFFFORTIME3    EFFGRAPHCHART3
 EFFDOSE3 EFFCS3 
  □ Mean weight loss _____lbs                     □ Graph/chart  Dose 
_____    □ CS 
 EFFMEANWEIGHT     EFFMWGRAPHCHART
 EFFMWDOSE EFFMWCS 
  □ Lose ___lbs in ____ days     □ Graph/chart   Dose 
_____    □ CS 
  □ Reduced Cholesterol _____ Æ ______  □ CS    □Anec 
EFFREDUCEDCHOLESTEROL        EFFCHOLESTTO EFFCHOLESCS  ANECDOTAL 
  □ Reduced Blood Pressure ____ Æ _____  □ CS    □Anec 
EFFREDUCEDBLOOD   EFFBPTO EFFBPCS  EFFBPANEC 
  □ Want to lose weight EFFWANTTOLOSEWEIGHT 
  □Keep weight off EFFKEEPOFFWEIGHT 
 
Mechanism       □ None Specified 
  □ inhibits fat absorption       □ appetite suppressant/controls hunger 
      MECHINHIBITSFAT           MECHAPPETITESUPPRESSANT 
  □ converts amino acids into muscle tissue     □ converts body fat to energy 
     MECHCONVERTSAATOMT         MECHBODYFAT 
  □ reduces body fat      □ increases lean muscle tissue   
     MECHREDUCESBODY        MECHINCREASESLEAN 
  □ reduces cholesterol levels MECHREDUCESCHOLESTEROL 
  □ oxidizes fat MECHOXIDIZESFAT    □ detoxifies body  MECHDETOXIFIES 
  □ reduces triglycerides levels/ stabilizes blood sugar MECHREDUCESTRIGLYCERIDE 
  □ contains lipotropics which help break down fatty deposits in the body 
MECHCONTAINSLIPOTROPICS 
  □ regulates/stimulates metabolism to burn fat/calories more effectively 
MECHREGULATESSTIMULATES 
  □ inhibits serotonin reuptake MECHINHIBITSSEROTONIN 
 
General Claims (Cont) 
Tolerance (No side Effects)    □ None specified TOLNONSPECIFIED 
  □ Well-tolerated by ________ patients TOLWELLTOLERATED 
  □ No increase incidence of valvular heart disease 
TOLNONINCREASEHEARTVALVEDISEASE 
  □ does not interfere with the natural absorption of vitamins and minerals 
TOLDOESNOTINTERFEREABSORP 
  □ non-addictive/ contains no caffeine or chemical stimulant 
TOLNONADDICTIVECONTAINSNOSTIMULANT 
  □ does not upset metabolism TOLDOESNOTUPSETMETA 
  □ safe TOLSAFE 
  □ no side effects TOLNOSIDEEFFECTS 
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Other Effects 
  □ lose/burn excess weight without changing diet or taking exercise 
OCLAIMSLOSEBURNEXCESS 
  □ provides essential nutrients OCLAIMSPROVIDESESSENTIAL 
 
Other Claims 
  □ “eat all you want” OCLAIMSALLYOUWANT 
  □ Convenient  (i.e once a day) OCLAIMSCONVENIENT 
  □ guaranteed resultsOCLAIMSGUARANTEED 
  □ ____ of people who use since _____ 
  □ Long-term effects have not been established 
     OCLAIMSLONGTERMEFFECTS 
  □ Weight Loss Dose Dependent 
     OCLAIMSWEIGHTLOSSDOSE 
  □ Effect on co-morbidities not established 
    OCLAIMSEFFECTONCOMORBIDITIES 
                 □ Other ________________________________ OCLAIMSOTHER 
 
      General Information about Obesity                      □ None specified  
                  
  □ Causes diabetes OBESITYINFOCAUSESDIABETES      □ Causes heart disease 
OBESITYINFOCAUSESHEART 
  □ Causes Hypertension OBESITYINFOHYPERTENSION  □ Causes arthritis 
OBESITYINFOCAUSESARTHRITIS 
 
    Contact Information (check all that apply) 
      □ No additional information CONTACTINFONOADDITIONAL 
      □ Address CONTACTINFOADDRESS □ Phone Number 
CONTACTINFOPHONENUMBER 
      □ Website CONTACTINFOWEBSITE □ Contact system 
CONTACTINFOCONTACTSYSTEM 
               □ Other________________________________ CONTACTINFOOTHER 
       Price Claims/Offerings  (check all that apply) 
                □ None PCONONE 
□ Cost savings      □ Coupons and discounts     □ Free 
brochure/booklet/Information kit 
PCOCOSTSAVINGS   PCOCOUPONSAND       
PCOFREEBROCHUREBOOKLETINFORMATION 
□ Money back guarantee      □ Free Product/trials     □ Support 
system/program 
PCOMONEYBACKGUARNTEE  PCOFREEPRODUCT 
 PCOSUPPORTSYSTEMPROGRAM 
□ Lack of Insurance Coverage PCOLACKOFINSURANCE 
                 □ Other ______________________________ PCOOTHER 
Superiority Claims         □ None SUPNONE 
            □ Comparison Product(s)               □ General Comparison   □ Placebo 
 SUPCOMPARISON   SUPGENERALCOMPARISON
 SUPCOMPARISONTOPLACEBO 
   Which Product:______________________ SUPWHICHPRODUCT 
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   Basis of Comparison:__________________ □ FTC Report    □ FTC Method     
 □ Either 
   SUPBASISOFCOMPARISON   SUPFTCREPORT        SUPFTCMETHOD 
 SUPFTCEITHER 
   Text of claim_______________________________________ SUPTEXTOFCLAIMS 
Nature of Ad Appeal (check all that apply) 
□ Anecdotal/Testimonial NOAANNECDOTALTESTIMONIAL 
□ Sex appeal NOASEXAPPEAL 
□ Safety/ Health & Nutrition NOASAFETYHEALTH 
□ Motivational/Optimistic MOTIVATIONALOPTIMISTIC 
□ Informative/Statistics & Studies NOAINFORMATIVESTATISTICS 
□ Fear Based NOAFEARBASED 
□ Promotional NOAPROMOTIONAL 
□ Humor/Witty NOAHUMORWITTY 
□ Emotional NOAEMOTIONAL 
□ Fun NOAFUN 
□ Celebrity Appeal NOACELEBRITYAPPEAL 
□ Popular NOAPOPULAR 
□ Best Selling NOABESTSELLING 
If Best Selling or Popular, how many products sold? ____________________________ 
NOAIFBESTSELLING 
 
Images of Inanimate objects  □ None IOIONONEDISPLATED 
□ Empty Plates #  □ Full Plates #   □Plates with Food Leftover # 
  
IOIOEMPTYPLATES  IOIOFULLPLATES  IOIOPLATESWITH 
□ Pamphlet for more information IOIOPAMPHLETFOR 
□ Tight Rope IOIOTIGHTROPE    □ Balance Bar 
IOIOBALANCEBAR 
□ Product IOIOPRODUCT 
 
Description Elaboration          
           
 IOIODESCRIPTIONTRBB 
 
Mechanism Images 
Anatomical Models  
□Brain   □ Intestines  □ Fat Molecules  □ 
Neurotransmitters 
MIBRAIN  MIINTESTINES  MIFATMOLECULES 
 MINEUROTRANSMITTORS 
Presence of   □ Drug Interaction within model or location of drug interaction 
   MIDRUGMOLECULES 
 
Advertising Programs Within Advertisement 
□ Advertising Weight Loss Program   Program Name:     
APWAADVERTISINGWEIGHT   APWAPROGRAMNAME 
 □ Healthcare counselors APWAHEALTHCARE 
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 □ Conversation Starter Kit APWACONVERSATION 
 □ Program Effectiveness  % 
 □ Tailored to each individual APWATAILOREDTO 
 □ Provide encouragement APWAPROVIDESENCOURAGE 
 □ Allows for realistic and achievable goals APWAALLOWSFORREALISTIC 
________________________________________________________________________
_ 
Complete this section if there are BODY PARTS depicted in the ad.  
 
Body Parts shown:             □ Yes                    □ No  BODYPARTSSHOWN 
Check all that apply:    
  
Person 1:       □ Torso          □ Arms              □ Legs          □ Back      □ Brain     □ 
Other__________ 
BODY1TORSO/BODY1ARMS/ BODY1LEGS/ BODY1BACK/BODY1BRAIN/ BODY1OTHER 
Person 2:       □ Torso          □ Arms              □ Legs          □ Back      □ Brain     □ 
Other__________ 
BODY2TORSO/BODY2ARMS/ BODY2LEGS/ BODY2BACK/BODY2BRAIN/ BODY2OTHER 
Person 3:       □ Torso          □ Arms              □ Legs           □ Back     □ Brain     □ 
Other__________ 
BODY3TORSO/BODY3ARMS/ BODY3LEGS/ BODY3BACK/BODY3BRAIN/ BODY3OTHER 
Person 4:       □ Torso          □ Arms              □ Legs           □ Back     □ Brain     □ 
Other__________ 
BODY4TORSO/BODY4ARMS/ BODY4LEGS/ BODY4BACK/BODY4BRAIN/ BODY4OTHER 
Person 5:       □ Torso          □ Arms              □ Legs           □ Back      □ Brain     □ 
Other__________ 
BODY5TORSO/BODY5ARMS/ BODY5LEGS/ BODY5BACK/BODY5BRAIN/ BODY5OTHER 
________________________________________________________________________
_ 
If there are NO before-after pictures in the ad but there ARE pictures of people, 
complete the following sections 
 
Person 1     Race      □ White      □ Black     □ Hispanic     □ Asian     □ Other     □ CBI 
 PERSON1WHITE/ PERSON1BLACK/ PERSON1HISPANIC/ PERSON1ASIAN/ 
PERSON1OTHER/ PERSON1CBI 
                   Gender   □ Male       □ Female           □ CBI 
  PERSON1MALE/ PERSON1FEMALE/ PERSON1GENDERCBI 
        Profession     □ Patient        □ Physician         □ CBI   
  PERSON1PATIENT/ PERSON1PHYSICIAN/ PERSON1PROFESSIONCBI 
 
                   Age        □ Child       □ Teen      □ Adult          □ Elder         □Infant     □ CBI    
 PERSON1CHILD/ PERSON1TEEN/ PERSON1ADULT/ PERSON1ELDER/ 
PERSON1INFANT/ PERSON1AGECBI 
                   Using Product           □ Yes        □ No     PERSON1USINGPRODUCT 
                   Weight lost (in lbs):_______ PERSON1WEIGHTLOSS                    □ N/A   
PERSON1WEIGHTLOSSNA 
                   Time on product: ______________  PERSON1TIMEONPROD        □ N/A  
PERSON1TIMEONPRODNA 
Gong 123 
                   Celebrity:     □ Yes        □ No     If Yes, Who:________________________  
  PERSON1CELEBRITY  PERSON1IFYESWHO 
            Weight before:_______   Weight after:_______  Total Weight 
Lost:________ 
 PERSON1WEIGHTBEFORE PERSON1WEIGHTAFTER
 PERSON1TOTALWEIGHT 
    Demeanor: 
            □ Sad/Stern         □ No particular expression       □ Happy/Smiling  
PERSON1SADSTERN     PERSON1NOPARTICULAR        PERSON1HAPPYSMILING 
    Clothing: 
             □ Bathing suit        □ Athletic/workout clothes        □ Casual                   □ Dress 
up 
PERSON1BATHINGSUIT        PERSON1ATHLETICWORKOUT     PERSON1CASUAL       
PERSON1DRESSUP 
     Social Depiction: 
             □ Alone PERSON1ALONE   □ With other people 
PERSON1WITHOTHERPEOPLE                   
If with other people    
□ Family PERSON1FAMILY  □ Romance PERSON1ROMANCE  □ Work 
PERSON1WORK   
□ Recreation PERSON1RECREATION □ Physician PERSON1PHYSICIAN   □ Patient 
PERSON1PATIENT 
□ Other ______________________ PERSON1SOCIALOTHER 
         
Person 2     Race      □ White      □ Black     □ Hispanic     □ Asian     □ Other     □ CBI 
 PERSON2WHITE/ PERSON2BLACK/ PERSON2HISPANIC/ PERSON2ASIAN/ 
PERSON2OTHER/ PERSON2CBI 
                   Gender   □ Male       □ Female           □ CBI 
  PERSON2MALE/ PERSON2FEMALE/ PERSON2GENDERCBI 
        Profession     □ Patient        □ Physician         □ CBI   
  PERSON2PATIENT/ PERSON2PHYSICIAN/ PERSON2PROFCBI 
                   Age        □ Child       □ Teen      □ Adult          □ Elder         □Infant     □ CBI    
 PERSON2CHILD/ PERSON2TEEN/ PERSON2ADULT/ PERSON2ELDER/ 
PERSON2INFANT/ PERSON2AGECBI 
                   Using Product           □ Yes        □ No     PERSON2USINGPRODUCT 
                   Weight lost (in lbs):_______ PERSON2WEIGHTLOSS                    □ N/A   
PERSON2WEIGHTLOSSNA 
                   Time on product: ______________  PERSON2TIMEONPROD        □ N/A  
PERSON2TIMEONPRODNA 
                   Celebrity:     □ Yes        □ No     If Yes, Who:________________________  
  PERSON2CELEBRITY  PERSON2IFYESWHO 
            Weight before:_______   Weight after:_______  Total Weight 
Lost:________ 
 PERSON2WEIGHTBEFORE PERSON2WEIGHTAFTER
 PERSON2TOTALWEIGHT 
    Demeanor: 
            □ Sad/Stern         □ No particular expression       □ Happy/Smiling  
PERSON2SADSTERN     PERSON2NOPARTICULAR        PERSON2HAPPYSMILING 
    Clothing: 
             □ Bathing suit        □ Athletic/workout clothes        □ Casual                   □ Dress 
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up 
PERSON2BATHINGSUIT        PERSON2ATHLETICWORKOUT     PERSON2CASUAL       
PERSON2DRESSUP 
     Social Depiction: 
             □ Alone PERSON2ALONE   □ With other people 
PERSON2WITHOTHERPEOPLE                   
If with other people    
□ Family PERSON2FAMILY  □ Romance PERSON2ROMANCE  □ Work 
PERSON2WORK   
□ Recreation PERSON2RECREATION □ Physician PERSON2PHYSICIAN   □ Patient 
PERSON2PATIENT 
□ Other ______________________ PERSON2SOCIALOTHER 
 
Person 3     Race      □ White      □ Black     □ Hispanic     □ Asian     □ Other     □ CBI 
 PERSON3WHITE/ PERSON3BLACK/ PERSON3HISPANIC/ PERSON3ASIAN/ 
PERSON3OTHER/ PERSON3CBI 
                   Gender   □ Male       □ Female           □ CBI 
  PERSON3MALE/ PERSON3FEMALE/ PERSON3GENDERCBI 
        Profession     □ Patient        □ Physician         □ CBI   
  PERSON3PATIENT/ PERSON3PHYSICIAN/ PERSON3PROFCBI 
                   Age        □ Child       □ Teen      □ Adult          □ Elder         □Infant     □ CBI    
 PERSON3CHILD/ PERSON3TEEN/ PERSON3ADULT/ PERSON3ELDER/ 
PERSON3INFANT/ PERSON3AGECBI 
                   Using Product           □ Yes        □ No     PERSON3USINGPRODUCT 
                   Weight lost (in lbs):_______ PERSON3WEIGHTLOSS                    □ N/A   
PERSON3WEIGHTLOSSNA 
                   Time on product: ______________  PERSON3TIMEONPROD        □ N/A  
PERSON3TIMEONPRODNA 
                   Celebrity:     □ Yes        □ No     If Yes, Who:________________________  
  PERSON3CELEBRITY  PERSON3IFYESWHO 
            Weight before:_______   Weight after:_______  Total Weight 
Lost:________ 
 PERSON3WEIGHTBEFORE PERSON3WEIGHTAFTER
 PERSON3TOTALWEIGHT 
    Demeanor: 
            □ Sad/Stern         □ No particular expression       □ Happy/Smiling  
PERSON3SADSTERN     PERSON3NOPARTICULAR        PERSON3HAPPYSMILING 
    Clothing: 
             □ Bathing suit        □ Athletic/workout clothes        □ Casual                   □ Dress 
up 
PERSON3BATHINGSUIT        PERSON3ATHLETICWORKOUT     PERSON3CASUAL       
PERSON3DRESSUP 
     Social Depiction: 
             □ Alone PERSON3ALONE   □ With other people 
PERSON3WITHOTHERPEOPLE                   
If with other people    
□ Family PERSON3FAMILY  □ Romance PERSON3ROMANCE  □ Work 
PERSON3WORK   
□ Recreation PERSON3RECREATION □ Physician PERSON3PHYSICIAN   □ Patient 
PERSON3PATIENT 
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□ Other ______________________ PERSON3SOCIALOTHER 
 
Person 4     Race      □ White      □ Black     □ Hispanic     □ Asian     □ Other     □ CBI 
 PERSON4WHITE/ PERSON4BLACK/ PERSON4HISPANIC/ PERSON4ASIAN/ 
PERSON4OTHER/ PERSON4CBI 
                   Gender   □ Male       □ Female           □ CBI 
  PERSON4MALE/ PERSON4FEMALE/ PERSON4GENDERCBI 
        Profession     □ Patient        □ Physician         □ CBI   
  PERSON4PATIENT/ PERSON4PHYSICIAN/ PERSON4PROFCBI 
                   Age        □ Child       □ Teen      □ Adult          □ Elder         □Infant     □ CBI    
 PERSON4CHILD/ PERSON4TEEN/ PERSON4ADULT/ PERSON4ELDER/ 
PERSON4INFANT/ PERSON4AGECBI 
                   Using Product           □ Yes        □ No     PERSON4USINGPRODUCT 
                   Weight lost (in lbs):_______ PERSON4WEIGHTLOSS                    □ N/A   
PERSON4WEIGHTLOSSNA 
                   Time on product: ______________  PERSON4TIMEONPROD        □ N/A  
PERSON4TIMEONPRODNA 
                   Celebrity:     □ Yes        □ No     If Yes, Who:________________________  
  PERSON4CELEBRITY  PERSON4IFYESWHO 
            Weight before:_______   Weight after:_______  Total Weight 
Lost:________ 
 PERSON4WEIGHTBEFORE PERSON4WEIGHTAFTER
 PERSON4TOTALWEIGHT 
    Demeanor: 
            □ Sad/Stern         □ No particular expression       □ Happy/Smiling  
PERSON4SADSTERN     PERSON4NOPARTICULAR        PERSON4HAPPYSMILING 
    Clothing: 
             □ Bathing suit        □ Athletic/workout clothes        □ Casual                   □ Dress 
up 
PERSON4BATHINGSUIT        PERSON4ATHLETICWORKOUT     PERSON4CASUAL       
PERSON4DRESSUP 
     Social Depiction: 
             □ Alone PERSON4ALONE   □ With other people 
PERSON4WITHOTHERPEOPLE                   
If with other people    
□ Family PERSON4FAMILY  □ Romance PERSON4ROMANCE  □ Work 
PERSON4WORK   
□ Recreation PERSON4RECREATION □ Physician PERSON4PHYSICIAN   □ Patient 
PERSON4PATIENT 
□ Other ______________________ PERSON4SOCIALOTHER 
 
 
Person 5     Race      □ White      □ Black     □ Hispanic     □ Asian     □ Other     □ CBI 
 PERSON5WHITE/ PERSON5BLACK/ PERSON5HISPANIC/ PERSON5ASIAN/ 
PERSON5OTHER/ PERSON5CBI 
                   Gender   □ Male       □ Female           □ CBI 
  PERSON5MALE/ PERSON5FEMALE/ PERSON5GENDERCBI 
        Profession     □ Patient        □ Physician         □ CBI   
  PERSON5PATIENT/ PERSON5PHYSICIAN/ PERSON5PROFCBI 
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                   Age        □ Child       □ Teen      □ Adult          □ Elder         □Infant     □ CBI    
 PERSON5CHILD/ PERSON5TEEN/ PERSON5ADULT/ PERSON5ELDER/ 
PERSON5INFANT/ PERSON5AGECBI 
                   Using Product           □ Yes        □ No     PERSON5USINGPRODUCT 
                   Weight lost (in lbs):_______ PERSON5WEIGHTLOSS                    □ N/A   
PERSON5WEIGHTLOSSNA 
                   Time on product: ______________  PERSON5TIMEONPROD        □ N/A  
PERSON5TIMEONPRODNA 
                   Celebrity:     □ Yes        □ No     If Yes, Who:________________________  
  PERSON5CELEBRITY  PERSON5IFYESWHO 
            Weight before:_______   Weight after:_______  Total Weight 
Lost:________ 
 PERSON5WEIGHTBEFORE PERSON5WEIGHTAFTER
 PERSON5TOTALWEIGHT 
    Demeanor:  
            □ Sad/Stern         □ No particular expression       □ Happy/Smiling  
PERSON5SADSTERN     PERSON5NOPARTICULAR        PERSON5HAPPYSMILING 
    Clothing: 
             □ Bathing suit        □ Athletic/workout clothes        □ Casual                   □ Dress 
up 
PERSON5BATHINGSUIT        PERSON5ATHLETICWORKOUT     PERSON5CASUAL       
PERSON5DRESSUP 
     Social Depiction: 
             □ Alone PERSON5ALONE   □ With other people 
PERSON5WITHOTHERPEOPLE                   
If with other people    
□ Family PERSON5FAMILY  □ Romance PERSON5ROMANCE  □ Work 
PERSON5WORK   
□ Recreation PERSON5RECREATION □ Physician PERSON5PHYSICIAN   □ Patient 
PERSON5PATIENT 
□ Other ______________________ PERSON5SOCIALOTHER 
 
Group of people (5 or more people) 
                   □ Group of people          □ No group of people 
        YESGROUPOFPEOPLE NOGROUPOFPEOPLE 
                    Race      □ White      □ Black     □ Hispanic     □ Asian     □ Other     □ CBI  
GROUPWHITE/GROUPBLACK/GROUPHISPANIC/GROUPASIAN/GROUPOTHER/GROUPRACEC
BI 
                   Gender   □ Male         □ Female                                 □ CBI 
   GROUPMALE/  GROUPFEMALE 
 GROUPGENDERCBI 
                   Age        □ Child       □ Teen      □ Adult          □ Elder                         □ CBI   
GROUPCHILD/GROUPTEEN/GROUPADULT/GROUPELDER/GROUPAGECBI 
  Social Depiction:            
□ Family      □ Romance    □ Work    □ Recreation   □ 
Other ______________     
GROUPFAMILY GROUPROMANCE GROUPWORK GROUPRECREATION
 GROUPSOCOTHER 
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Appendix 5: Coding Tool Descriptors 
Unique Ad, Product, and Manufacturer Numbers:  
 The unique ad number can be found on the upper right hand corner of the 
advertisement on a post-it. The Product and Manufacturer numbers can be found in the 
attached spreadsheets. 
 
 
Ad Length 
 If the ad is less than one page you will have to measure the size of the ad with a 
ruler, in inches. The width is the ad size from left to right while the length of the ad is 
from bottom to top. 
 
 
Product Type:  
 The product type describes in what form the product is presented to the customer 
or patient.  There are many different product types and some ads have more than one item 
(a low carbohydrate bar with an accompanying bottle of capsules). If that is the case, 
check as many product types as there are presented. If you are sure that the product is a 
pill but not sure if it is a tablet or a capsule check off “Unspecified Pill.”  If the type of 
product is not mentioned in the ad, check “not specified”.   
 
Design of ad 
 Specify whether the ad is in color, black & white, or microfiche.  The microfiche 
ads are in black and white and have poorer resolution, these are not meant to be black and 
white but are stored that way in the library/digitally. 
 
Ad Visual 
 Ad visual describes the objects in the ad.  Specify whether the ad contains text, 
pictures, product, charts, quizzes, or questionnaires, and be sure to check all that apply. 
 Pictures are not just photographs but can be cartoons, people, etc.  Products do not 
count as pictures.   
Product can be in the form of the packaging (box, bottle etc.) or actual product form 
(tablet, capsule).   
Charts don’t have to be specifically outlined as a formal chart.  Sometimes they are subtly 
conveyed within the marketing figures as risk meters or steps in product dosage.  For 
example BEHO.03-03.PH.LIPITOR.1 has a chart next to the woman, demonstrating her 
characteristics and cholesterol level. 
Quizzes and questionnaires don’t need to be specifically outlined as such but can be 
conveyed through a series of questions with space for “answers” and with or without 
provided “answers”. 
Testimonials are any enlarged quote next to a person, or if there is a quote with a person 
telling about their experience with the product. 
 
 
Tagline 
Gong 128 
 Write in the tagline and corresponding tagline number that appears in the 
advertisement.  If there is no tagline in the ad check the “no tagline” box. 
 Taglines are not just a recurring phrase in multiple ads, a tagline should be a 
phrase associated with the brand/product that is seen in multiple different types of 
advertisement for the same product.  For example, some phrases may be used multiple 
times but within the same advertisement theme.  These are not taglines but phrases used 
for a specific ad campaign.  We want taglines to be associated with the brand/product, not 
specific ads/series of ads. 
 
 
 
 
Directives, Side Effects, and General Claims do not have to say exactly what is listed 
on the coding form.  The coding form embodies general statements that could refer 
to more specific claims and information found in individual advertisements.  Check 
all that apply for these categories. 
Use “Other” boxes sparingly, most important statements have been accounted for 
and if they are too specific will not be useful to us.  Make sure that it is pertinent to 
Directives, Side Effects, Claims, or Information and that it hasn’t already been 
accounted for in one of the boxes. 
 
Directives 
 Directives are specific instructions given in the advertisement to be carried out 
with administration of the product.  The section is divided into a section that gives 
directives for those taking the medicine and a part that lists those who are not directed to 
take the medicine.   
Directives are often implied but should still be marked.  For instance “avoid possible 
dangerous drug interactions” should be marked when an ad tells you to talk to your 
doctor about other medications you are taking when using product ___. 
 
Side Effects 
 Side effects of the product are listed in the print of most ads. Check all side 
effects that apply to the given product.  Some side effects are very product specific and 
are not listed. Write these out in the “other” category.   
Dyspepsia should be included in upset stomach/pain/nausea and arthralgia in 
muscle/joint/bone pain.   
 Do not go through the warnings page to find additional side effects, include only 
those listed in the promotional part of the ad. 
 
 
 
General Claims 
 These are general claims that the manufacturers make, describing how the product 
works, success rates, statistics/studies on the product, and what differentiates it from 
other products in the field.  Preventative claims are before the condition sets in, the 
product claims that it will help to deter the onset of the condition.  Treating claims are 
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directed toward relieving the symptoms of a specific condition.  Reversal claims aim to 
show the product can reverse degenerative symptoms and bring back normal health. 
Be VERY careful in this section. There are a lot of possible claims. Go through the ad 
line by line and see if there is anything you can check off. 
 
 
Price Claims/Offerings 
Any claims about the price of the product that the manufacturer makes in the 
advertisement should be included in this section.  Offerings are deals, discounts, rebates, 
merchandise etc. that the manufacturing company offers the customer through their 
advertisement.  If a claim or offer is made that is not specifically listed on the coding 
form write it in the “other” line.  Support systems/programs refer to any additional help 
given by the product manufacturer/company beyond just information (i.e. insurance 
coverage, consumer hotlines, programs etc.). 
 
Pricing 
 In this section you are to fill out the price and then the supply. The supply can be 
given in how many days, weeks, months, or pills the price will allow. Fill out as many 
price sections as are offered in the ad. If they accept Credit Cards, make sure to check off 
the box. If they have any Shipping/Handling information, be sure to check off the box 
and write it in. 
 
Contact Information 
This pertains to the information of the company manufacturing the product.  Most often 
includes contact, product information, informative questionnaires, and self-tests.  Check 
boxes pertain to how the information is distributed. 
 
Nature of Ad appeal 
 Ad appeal refers to how the advertisement convinces the consumer to purchase 
the product.  Unlike product claims nature of ad appeal is what marketing technique is 
used beyond the characteristics of the product.  Check all that apply, many ads will use 
more than one advertising technique.  Informative is the default ad appeal if nothing else  
is used; nature of ad appeal is a required field. 
 Remember that the Nature of Ad appeal is the specific marketing technique used 
in the advertisement so the appeal is explicitly conveyed, not subtly referred to. 
 
    Anecdotal- Ad appeal is based on a specific person’s experience/story with the 
medication or illness.  These will have ads based on people’s subjective experiences with 
the product or condition.   
           i.e. I exercise, eat right, but still overweight…until I took ________ 
An ad is not anecdotal/testimonial if it just has a picture of someone next to the product 
and it looks as if they used the product.  There must be some sort of explicit “testimony” 
or story about how they used the product/had the condition. 
 
    Fear-based- ad appeal is based on scaring you into purchasing the product by 
expanding on the severity of the illness and making drastic statements like “your kids just 
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want you around for the future”- suggesting that if you want to be around for the future 
you’ll get their medication. 
 
   Safety- emphasizes how safe/low risk of side effects the medication is.  This is only 
part of the ad appeal if the advertisement makes a point to highlight the safety of the 
product. This box should be checked if the ad makes a lot of claims about how nutritious 
their product is.  Needs to be more than just a statistic or statement about low risk of side 
effects. 
  
   Motivational - has a “you can do it” attitude.  Tries to pick you up and get you normal 
again, these ads reach out to the consumer and make them feel like there is a solution to 
the condition.  “You can do it! We can help”   
Motivational must be overt and beyond statements that the drug works to cure a 
condition, these must be part of the “ad appeal”, specifically marketed as motivational. 
 
   Informative/Statistics and Studies- gives empirical evidence of the medicine’s 
effectiveness or the prevalence of the disease through specific statistics or clinical trials.  
The statistics referred to are based on studies or research (i.e. FatBlocker helped  90% 
people, FatbBlocker lowers body fat 43% average etc.), not % decrease in fat from one 
person.  An ad is informative if it does not include obvious information. 
Information to be included in “informative” should be the main text of the article; an ad is 
not informative based on the fine print text, including “important information about” ___. 
      *This is also the default appeal if no other technique is used. 
Not every ad is informative    
      * Claims and advertising opinions are not informative.  (i.e. best, most, safest etc.) 
 
    Popular Appeal- Makes you feel like you’re not alone, many other people suffer from 
the same symptoms as you and take medication for it.  “18 million Americans suffer from 
depression”.   
 
Emotional- Linking depression or sadness to obesity. “I was upset all of the time, until I 
tried Carb Solution.” Must have an explicit link to a change in emotion because of the 
product. 
 
Stressing Activity or Exercise: Placing a large emphasis on exercise in conjunction with 
the product. Needs to be more that just than a woman in a workout outfit. 
 
Best-selling- Tells you how many other people have bought the product “… is the best 
selling medication for weight loss”. 
    
 Promotional- Focus is to promote the product through special offers, coupons, 
guarantees, promotions, etc. 
Preview ads are always promotional -  they are promoting the introduction of the product. 
 
Humor/witty – any comedic or witty advertisements, whether overt or subtle 
o plays on words, intended ridiculousness, social satires, rhymes 
Gong 131 
o taglines can be considered humor/witty and all ads with them should be 
coded as such however not all taglines are necessary humor/witty 
o you must analyze the intent of the advertisement, not your personal belief 
of whether or not you think the ad is funny 
 
Sex Appeal - provocative, revealing clothing, suggestive poses, etc. 
Less obvious partial nudity such as exposed shoulders, midriff, legs is still 
considered seductive/sexy 
o may be ad with one or multiple people in it 
e.g. man without shirt, woman in bathing suit, seductively flowing 
skirts   
ALSO a woman at a bar or people at a dance club with seductive poses 
or facial expressions may count as seductive 
* do NOT base decision only on facial expression, unless 100% surely seductive  
 
 
 
Superiority Claims 
 Refer to explicit comparisons of all products in the product category/genre or a 
specific competitor/leading brand.  If a specific competitor is mentioned write the 
competitor below.  Fill in the basis for comparison, study/test used to compare it to other 
brands regardless of specific comparisons. 
 
Before and After Pictures (Over the counter only):  
 First, you must decide if there are FULL BODY before and after pictures. A 
before and after stomach shot does not count. If there are, record how many and start to 
code them. Race/gender/age/celebrity status do not change and you only have to do those 
once. For “using product” there has to be a SPECIFIC connection to words and a person. 
Only EXPLICIT references to people using the product count.  There are three 
before/after characteristics you should code: Demeanor/Clothing/and Social Depiction.  
 
Body Parts 
  This section is if there are pictures of just body parts. This section is NOT if one 
person’s thigh is visible. This section IS for just a picture of a thigh.  
  
People in Ad 
 If there are 5 people or less in the ad, go through and code them according to race, 
gender, age, whether or not they are using the product, and whether or not they are a 
celebrity.  For categories that may be difficult to see or are fairly ambiguous mark CBI 
(cannot be identified).  Do not guess individuals’ characteristics such as race, gender, age 
etc.  When coding multiple people, code foreground/focus of the ad first and background 
people next.  All people should be coded from left to right.  i.e., 2 people in front and 3 
people in back.  Code front left, front right, back left, middle, right in that order.  For 
people not arranged in the same picture and in a circular format, code using clock format 
starting at noon and rotating clockwise.  i.e. 4 separate pictures/people in a square pattern 
on the page.  Start with top right picture/person, bottom right, bottom left, top left in that 
order. 
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Group of People 
 If there are more than 5 people in the ad, mark all boxes that apply using the same 
categories as People in Ad.  If there is a group of people don’t mark off all the individual 
boxes, just the group box.  However, still mark people in the individual people category 
but leave all the individual boxes blank. 
 Characteristics should pertain to the group as a whole, so mark all that apply.  i.e. 
multiracial, multi-gender ads should mark all races present and both male and female. 
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Appendix 6 – Variable Measurement 
 
Hypothesis 1: Determining the target audience of the advertisement 
Due to the inclusion of the multiple individuals within an advertisement, there 
was a need to determine who the target population was in the advertisement.  Appendix 
6, figure 1 displays how just using the raw data from the content coding tool can skew the 
results.  The use of a baby and a male physician should not be included in the analysis of 
the firms’ ability to target a specific audience through choosing specific magazines.  
Appendix 6, figure 2 displays an advertisement displayed toward a female audience.  
Appendix 6, figure 3 displays an advertisement displayed to both males and females.  In 
this image, the presence of two females and one male presents the inability to determine 
the exact target population of this advertisement.   
 
Hypothesis 2: Determining Nature of Advertisement Appeal and Depiction of Individuals 
In analyzing the nature of advertisement appeal, the occurrence of multiple 
appeals can occur within the same advertisements Figures 4, 5, 6, 7, and 8 represent a 
specific advertisement appeal to clarify the major appeal within the advertisement.  
Although figure 4 presents an image of a female waist line, the appeal is predominantly 
informative because it includes the mechanism of action and the chemical.  Figure 5 is 
anecdotal because of the multiple before and after images and the quotes from actual 
users.  Figure 6’s primary appeal is safety, health, and nutrition because the 
advertisement claims the individual does not need to starve or over-exercise to lose 
weight.  Figure 7 represents a sex appeal advertisement.  The inclusion of Bodylove as 
the name brand and the pose and clothing of the individual presented in the advertisement 
creates an appeal that is sexual in nature. 
To describe the depiction of individuals, figure 9 covers most of ways individuals 
are portrayed in these advertisements.  The first two individuals within the advertisement 
dressed in casual white clothes represent individuals who are with a significant other who 
appear to be happy and smiling.  The other male individual within the advertisement who 
is wearing red shorts and a blue shirt can be considered wearing athletic clothes with no 
particular facial expression.  The female gardening can be considered alone, wearing 
casual clothes with no particular facial expression.  The female rollerblading was 
considered wearing athletic clothes and happy and smiling.  The female the red dress in 
figure 5 is an individual who can be considered wearing dress-up clothes.   
 
Hypothesis 5: Use of Product Differentiating Claims 
The use of product differentiation claims is extremely prevalent in this class of 
drugs due to the reports of adverse events as well as the voluntary withdrawals.  The 
product differentiation claims are identified in red squares in Figures 3, 10, 11, 12, and 
13.  These are examples of what constitutes a product differentiation claim.   
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Figure 1 – Xenical Advertisement  
SCADS Database 
Appeared in Family Circle - April 24, 2001 
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Figure 2 – Xenadrine Advertisement 
SCADS Database 
Appeared in Vogue - January 2002 
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Figure 3 – Xenadrine Advertisement 
SCADS Database 
Appeared in People - March 6, 2002 
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Figure 4 – Ellotrim Advertisement 
SCADS Database 
Appeared in Woman’s Day - December 15, 1998 
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Figure 5 – Hydroxycut Advertisement 
SCADS Database 
Appeared in Woman’s Day - June 4, 2002 
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Figure 6 – Thyrolean Advertisement 
SCADS Database 
Appeared in Glamour - March 1999 
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Figure 7 – Chitosan Advertisement 
SCADS Database 
Appeared in Glamour - July 1999 
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Figure 8 – Curves Advertisement  
SCADS Database 
Appeared in Woman’s Day - March 31, 1997 
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Figure 9 – Meridia Advertisement 
SCADS Database 
Appeared in New England Journal of Medicine - June 24, 1999 
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Figure 10 – Meridia Advertisement  
SCADS Database 
Appeared in New England Journal of Medicine - September 3, 1998 
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Figure 11 – NxTrim Advertisement 
SCADS Database 
Appeared in Vogue - March 1999 
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Figure 12 – Meridia Advertisement 
SCADS Database 
Appeared in   – February 1999 
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Figure 13 – Xenical Advertisement 
SCADS Database 
Appeared in Family Circle – March 13, 2001 
 
 
